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CHAPTER I 
 
INTRODUCTION 
 
The Discovery of Viruses 
 
Viruses were first discovered in 1898 when Martinus Beijerinck showed that a 
particular infection of tobacco plants could be transmitted even when using filtered and 
bacteria-free media.1, 2  According to the germ theory of disease at that time, all infectious 
agents could be removed with filtration.3  Further, all infectious agent could be 
propagated on an appropriate nutrient medium.3  Both of these principles were found to 
be untrue for the infectious agent Beijerinck was working with; which later came to be 
known as tobacco mosaic virus (TMV).1, 2  In 1939, Gustav Kausche and Helmut Ruska 
showed that TMV could be crystallized and analyzed via electron microscopy.4  Up until 
this point, viruses had not been imaged because they were too small to see using an 
optical microscope.   
These infectious agents were interesting for a number of reasons.  First, their 
extremely small size, ~300 nm in length and 17 nm in diameter, made it possible for the 
virus to pass through filters that other infectious agents, such as bacteria, could not.5  
Second, the fact that the virus required a host to propagate precluded it from being 
cultured strictly on a nutrient medium.2  Finally, even after crystallization, the agents 
were still infectious.6  Although these attributes confounded scientists of the day, modern 
techniques have allowed for a much greater understanding of the intricacies of viruses. 
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One common attribute of viruses is their need of a host to proliferate.7  Viruses 
need a host to proliferate because they lack their own metabolism and therefore, are not 
considered living organisms.8  This concept is further emphasized by the fact that virions 
can multiply by spontaneously assembling within host cells instead of through cell 
division.9  However, it is interesting to note that like living organisms, virus do possess 
genes and evolve by natural selection.10 
 
The Anatomy of a Virion 
 
A virus particle, known as a virion, consists of a minimum of two parts.7  The first 
is genetic material, which is composed of DNA or RNA.  The genetic material acts as a 
blueprint to encode information about the proteins associated with the virus.  Even at the 
level of genetic material, a large amount of diversity can be observed.  The viral genome 
can be single-stranded DNA (ssDNA), double-stranded DNA (ds-DNA), or RNA.  If the 
genome is ssDNA or RNA, it can be positive-sense or negative-sense.  RNA genome are 
often further divided in segmented and nonsegmented genomes.  The second part of a 
virion is the protein coat.   The protein coat serves as protection for the genetic material.  
It is the formation of the protective protein coat that dictates the structure of the virus, 
which can range from simple helical or icosahedral structures to much more complex 
structures.11, 12  Often times, in addition to protection of the genetic material, the proteins 
associated with the virus will serve additional functions.  Some proteins can mediate cell 
fusion or cell attachment; others can serve as a viral polymerase once the virus is inside a 
host cell.13  Some viruses are characterized by having a third part, a lipid envelope which 
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surrounds the protein coat.7  The lipid coat is obtained from one of host cell’s membranes 
and is typically interlaced with viral proteins.  All of these factors contribute to the 
diverse morphologies observed in viruses (Figure 1).   
 
 
Figure 1.  Electron micrographs of different viruses to illustrate the diverse morphologies of viruses.  
A) Ebolavirus.  B) Respiratory Syncytial Virus.  C)  Herpes Simplex Virus.  D) Bacteriophage T7.  E) 
Marburg Virus.  F) Rotavirus.  Images are public domain and courtesy of the Public Health Image Library. 
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Respiratory Syncytial Virus 
 
 Currently, there are over 2000 recognized species of viruses.14  One common 
virus in infants, respiratory syncytial virus (RSV), infects nearly all children by the age of 
three.15  RSV was first isolated in 1956 from a chimpanzee presenting a common cold-
like illness.16  Soon after, the virus was found in infants with respiratory illness, and now 
it is recognized as the leading cause of lower respiratory tract infections in infants and 
young children.17, 18   
RSV is classified in the family Paramyxoviridae, order Mononegavirales.13  It is 
an enveloped virus with a nonsegmented negative-strand RNA genome.  The 15.2 
kilobase genome of RSV encodes 11 identified proteins.13  Three of the genes encode 
transmembrane surface glycoproteins, the fusion protein (F), attachment protein (G) and 
small hydrophobic protein (SH), which coat the lipid envelop of the virus (Figure 2).13  
The F protein facilitates viral entry into a potential host cell through fusion of the viral 
envelop with the plasma membrane of the host cell.19, 20  The G protein serves as the 
major attachment protein, and although it is not required for virulence, it does increase 
infectivity.21, 22  The direct role of the SH protein in RSV infection is still unclear.13  Four 
of the other genes encode the five proteins that make up the nucleocapsid/polymerase 
complex.  The nucleocapsid/polymerase complex is composed of the nucleoprotein (N), 
large polymerase subunit (L), phosphoprotein (P), M2-1 and M2-2 cofactors.13, 23  The N 
protein encapsidates genomic RNA to form an RNase-resistant nucleocapsid.13  The L 
protein serves as the RNA polymerase for replication and transcription.24, 25  The P 
protein serves as a chaperone for soluble N protein as well as positions the L protein on  
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Figure 2.  Viral structure of respiratory syncytial virus. The structure shows 1) the location of the 
transmembrane surface glycoproteins (F, G and SH) interlaced in the lipid bilayer envelope of the virion, 2) 
the location of the matrix protein (M) associated with the interior of the lipid bilayer, 3) the phosphoprotein 
(P) associated with soluble N protein and positioning the L protein on the viral RNA, 4) the large protein 
(L) complexed with both P protein and viral RNA, and 5) the nucleoprotein (N) bound to viral RNA 
forming an RNase-resistant nucleocapsid.  
 
the RNA template.13, 24  M2-1 serves as a transcription antitermination factor while M2-2 
acts to regulate RNA synthesis.24, 26-28  A ninth encoded protein, the matrix protein (M), 
mediates the association of the viral nucleocapsid with the lipid envelop.13  The 
remaining two proteins, nonstructural proteins one and two (NS1 and NS2), are not 
believed to have a significant role in virus assembly and their specific roles are still 
undefined.13  All of these features of the virus can serve as potential biomarkers of an 
infection. 
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Detecting a Viral Infection:  Conventional Diagnostics 
 
Currently, there is no approved vaccine for RSV, and treatment options are 
limited.29-31  However, progress in antiviral therapeutics could offer a promising 
treatment option if the virus can first be accurately diagnosed.  In addition to effective 
treatment, diagnosis is important for patient placement to limit nosocomial 
transmission.32  Traditionally, viral infections have been detected using a number of 
means including cell culture, serology, antigen detection and nucleic acid detection.33 
Cell culture techniques of virus detection date back to 1948 when the first 
description of viral isolation in cell culture was described by Thomas Weller and John 
Enders.34  This technique involves the growth of a virus in cell cultures and the detection 
of the virus through morphologic changes in cells as a result of the infection, also known 
as the cytopathic effect (CPE) of the virus (Figure 3).35  One distinct advantage of viral  
 
 
Figure 3.  Cytopathic effects of RSV on HEp-2 cells.  A) A confluent monolayer of uninfected HEp-2 
cells.  B)  HEp-2 cells 60 hours post infection.  Post RSV infection, large multinucleated cell-like structures 
(red arrows) termed syncytia are present as a result cell to cell fusion by F protein expressed on the surface 
of infected cells.  Also, post infection holes in the monolayer (green arrows) are present as a result of cell 
death. 
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culture over other diagnostics is that the technique provides a viable isolate that can be 
used for further characterization.  However, the utilization of viral culture techniques as 
diagnostics is diminishing as it comes with a number of drawbacks.  First, no one cell 
type can support the growth of all viruses, so multiple cells lines must be kept on hand 
and unknown viruses must be tested in a variety of cell lines.33  Second, detection via 
CPE can be slow and can take upwards of 3 weeks for some viruses to induce 
morphologic changes in the cells and requires expertise to evaluate.33  Finally, viral 
culture places increased weight on specimen handling and transport as the specimen must 
contain viable virus in order for the technique to work.33 
The drawbacks of viral culture have led to its gradual replacement by antigen 
detection techniques.  Antigen detection utilizes specific antibodies to detect viral 
specific proteins to identify the presence of an infection.36  These methods are 
particularly useful for viruses that are difficult to culture or grow slowly in culture.37, 38  
In addition to the increased flexibility in pre-assay handling because the virus does not 
need to be viable, direct antigen methods are typically much faster than viral culture 
techniques.  Furthermore, the number of antigens per virion provides multiple targets per 
virion and gives an increase in the initial target concentration when compared to viral 
culture.  The most common antigen detection techniques are fluorescent antibody (FA) 
staining and enzyme immunoassays (EIA). 
Fluorescent antibody staining was first described by Liu in 1956 for the detection 
of influenza.39  However, it wasn’t until specific monoclonal antibodies became 
commercially available that the technique became widely used in clinical labs.34  FA 
staining involves the mounting of specimen cells to a glass slide.  The cells are then fixed 
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and blocked.  Finally, the cells are labeled with virus specific antibodies conjugated to a 
fluorophore.36  The slide is then viewed under a fluorescence microscope and the 
presence of fluorescent staining indicates the presence of an infection.  FA staining 
allows multiplexed detection using different specific antibodies labeled with different 
fluorophores and the appropriate excitation/emission filters. 
Enzyme immunoassays were developed as a derivative of radioimmunoassays 
(RIA).  First published by Rosalyn Yalow and Solomon Berson in 1960, RIAs required 
the use of radioactively-labeled antibodies to detect antigen.40   Later, EIA was developed 
to address the safety concerns of working with radioactive compounds by utilizing 
enzymes and a colorimetric change instead.  In 1971,  two groups: 1. Peter Perlmann and 
Eva Engvall, and 2. Anton Schuurs and Bauke van Weemen independently developed 
methods on EIA, or as Perlmann and Engvall termed them, enzyme-linked 
immunosorbent assays (ELISA).41, 42 
A “sandwich” ELISA is the typical EIA used to detect the presence of virus in 
infected cells (Figure 4).  In a sandwich ELISA, a protein binding substrate is coated 
with antibodies specific to the virus of interest.  The substrate is then blocked to displace 
non-specific interactions and then incubated with the specimen.  The capture antibodies 
will bind to antigen in the sample and prevent the antigen from being washed away on 
subsequent washing steps.  Finally, the captured virus is incubated with a second 
antibody that is conjugated to an enzyme; often times horseradish peroxidase (HRP) is 
used as the enzyme.43  If virus is present in the sample, the second antibody will form a 
“sandwich” complex with the antigen and the capture antibody.  However, if virus is not 
present in the sample, the second antibody, along with the coupled enzyme, will be 
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washed away.  Upon addition of a colorimetric substrate, a color change will be observed 
if the second antibody is still present. 
Using an ELISA to detect viruses has a number of strengths.  First, the 
colorimetric signal can be detected using a spectrophotometer, making its interpretation 
more objective than monitoring CPE.  Second, the use of protein binding microtiter plates 
allows for automation and parallel analysis of many samples at once.  Finally, analysis is 
quick and can be accomplished in a matter of hours instead of days like viral culture.  
However, ELISA, like many traditional direct antigen detection methods, suffers from a 
lack of sensitivity resulting in a high false negative rate. 
 
 
Figure 4.  Detecting viruses with a sandwich ELISA.  In a sandwich ELISA, capture antibodies (black) 
are first bound to a microtiter plates.  The sample of interest is then incubated in the microtiter plate to 
allow capture of any antigen (green).  Following washing and blocking, primary antibody (blue) is added to 
form a “sandwich” complex with antigen and capture antibodies.  An enzyme linked, secondary antibody 
(orange) is then added to label any formed sandwich complexes.  A colorimetric substrate (white) is then 
added to detect the presence of the enzyme (light blue), and in turn antigen. 
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A more recent viral diagnostic is the use of nucleic acid detection.  The 
development of the polymerase chain reaction (PCR) in 1983 by Kary Mullis, allowed 
nucleic acid sequences to be amplified, increasing the number of copies several orders of 
magnitude.44  The technique was extended to the detection of diseases by Randall Saiki in 
1985.45  Nucleic acid diagnostics were expanded with the development of reverse 
transcriptase PCR (RT-PCR), which allowed any virus to be detected using nucleic acid 
detection.33  RT-PCR allows for the detection of RNA viruses by first reverse 
transcribing their genomes or mRNA into cDNA which is subsequently amplified and 
detected.  The use of real-time thermocyclers has further solidified the use of nucleic acid 
detection as a clinical diagnostic tool.  Currently, PCR-based diagnostics remain the gold 
standard for sensitive detection of virus.  The amplification power of PCR allows for a 
much lower limit of detection than traditional direct antigen diagnostics.  However, 
nucleic acid diagnostics are not without their drawbacks.  Because of the inherent 
amplification potential of these diagnostics, even small amounts of cross-contamination 
can result in false positives.  Additionally, lysis of the cell to release viral genetic 
material also releases DNases and RNases which can degrade the viral DNA or RNA that 
is being detected.  This places increased attention on pre-assay handling and storage as 
compared to direct antigen diagnostics. 
Serology has also been utilized to diagnose a viral infection.  Serological methods 
detect specific antiviral antibodies in order to detect the presence of an infection.46  These 
methods provide a different level of information than the previously discussed methods.  
An immunological response is what is actually being detected, and although it is 
informative to know if an immunological response is present, it does not tell the whole 
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story of the infection.47  Often times, the immunological response lags behind the initial 
infection so that there is an inherent window when a serological method would give a 
false-negative because the immunological response has not begun.  Additionally, 
serological results can be confusing when dealing with chronic infections, such as RSV, 
where residual antibodies tend to linger after the infection has passed. 
 
Detecting a Viral Infection:  Modern Diagnostics 
 
Although techniques for detecting viral infections have greatly improved over the 
last 60 years, there are still a number of shortcomings with conventional diagnostics.  No 
single technique can meet all the criteria of being rapid, sensitive, specific and simple.  In 
the interest of continuing to improve diagnostics, a number of modern techniques have 
been developed which offer a novel approach to detection.48  These new techniques range 
from the use of atomic force microscopes (AFM) to the use of magnetic nanoparticle and 
fluorescent semiconductor quantum dots. 
AFM has not only been used to visualize viruses, but more recently it has been 
used to detect them (Figure 5).49-51  AFM measures the deflections from a cantilever tip 
that scans a given surface.52  As the height of the surface changes, the amplitude of the 
oscillations of the tip also changes.  These changes are then detected by a laser that is 
deflected off of the tip to a photodiode detector.  In these experiments, an array of 
antibodies specific to different viruses was printed onto a protein binding substrate.  The 
printing process provided spatial control of where each type of antibody was placed.  The 
substrate could then be incubated with cell lysate.  In the presence of an infection, antigen 
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would be captured by the specific antibody along the array.  As the AFM tip taps along 
the surface, binding of antigen can be detected by an increase in the height of the surface.  
This technique provided a number of benefits as a viral diagnostic.  Using the AFM tip 
itself as a detector made the assay completely label-free.  The use of an array of 
antibodies allowed for the detection of multiple viruses at once.  Additionally, the change 
in height provides a definitive diagnosis.  It was also shown that the sample matrix 
showed very little interference with the final result.  However, the limit of detection of 
 
 
Figure 5.  Immunocapture AFM.  The “ViriChip,” which contained an array of different specific 
antibodies, is incubated with the sample of interest.  In the presence of virus, antibodies specific to that 
virus will bind antigen.  The array is then analyzed via AFM.  As the cantilever (dark gray), taps along the 
surface of the array, a photodiode detector (yellow) records the oscillations of a laser (red) that is being 
deflected by the cantilever.  Binding of antigen causes a change in the amplitude of the cantilevers 
oscillation which is then detected by the photodiode detector as a change in the oscillation of the laser. 
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AFM diagnostic was quite high (106 – 107 TCID50/mL), making it no more sensitive than 
conventional direct antigen diagnostics.48  Without an increase in sensitivity, the need for 
specialized equipment and trained personnel outweighs the benefits of the AFM 
diagnostic. 
Another modern diagnostic that has been recently reported is the use of 
functionalized magnetic nanoparticles to detect viruses (Figure 6).  Magnetic 
nanoparticles can enhance the T2 relaxation times of surrounding water molecules by de-
phasing the spin of the protons in water molecules.53  Magnetic resonance imaging (MRI) 
can detect these changes in relaxation times.  By attaching virus specific antibodies to the 
magnetic nanoparticles, it is possible to form assemblies of nanoparticle-virus 
complexes.54  These assembles can then be detected to indicate the presence of a virus.  It 
 
 
Figure 6.  Viral-induced assemblies of antibody functionalized magnetic nanoparticles.  In the 
presence of virus, antibody functionalized magnetic nanoparticles bind antigen and form larger 
nanoparticle-virus complexes.  The formation of these complexes can then be detected via MRI. 
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has been shown that by using a MRI, it is possible to detect as few as five virus particles 
per 10 µL.48  In the presence of virus, an initial bimodal population distribution exists, 
corresponding to the magnetic nanoparticles (46 nm) and the virus (100 nm).  After 30 
minutes, however, the population representing the virus disappears and is replaced by a 
larger population (494 nm) representing the nanoparticle-virus complex.48  The use of 
magnetic nanoparticles provides both sensitive and rapid detection of virus.  
Unfortunately, these attributes are offset by the need for expensive equipment like a MRI 
and the difficulty of multiplexed detection.  
Recently, fluorescent semiconductor nanocrystals (QD) have been used to 
improve traditional FA staining (Figure 7).55  QDs offer a number of advantages over  
 
 
Figure 7.  Improved photostability of QDot FA staining.  RSV F protein labeled with A) Fluorescein 
conjugated secondary antibody and C) biotin conjugated secondary followed by streptavidin 605 Qdots.  
After 1 minute of continuous illumination, B) Fluorescein labeled sample show extensive photobleaching, 
while D) QDot labeled samples show no change in intensity. 
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standard organic fluorophores:  1. QDs are extremely bright, offering increased 
sensitivity, 2. QDs have better photostability than organic fluorophores, and 3. QDs have 
a broad absorption and narrow emission spectra to allow for multiplexed detection.  The 
use of QDs improved the limit of detection of FA staining and allowed for the detection 
of as few as 35 PFU/well only 24 hours after infection when using a plate reader to detect 
fluorescence.48  Using an epifluorescence microscope, these same samples could be 
detected as early as one hour post infection.48  It is clear that simply changing FA staining 
protocols to utilize QDs instead of organic fluorophores improved FA detection with little 
to no additional cost. 
 
Conclusions 
 
 Although viral diagnostics continue to improve, it is clear that an ideal diagnostic 
does not yet exist.  As new technologies become available, they need to be integrated into 
diagnostics to continue to improve upon existing diagnostics while completely new 
approaches should be explored also.  Improved diagnostics will not only help physicians 
in their course of treatment, but also help encourage the development of new antivirals.  
If it is possible to accurately and quickly diagnose a virus, the motivation to develop new 
therapeutics for that virus will increase. 
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CHAPTER II 
 
VIRAL DETECTION USING DNA FUNCTIONALIZED GOLD FILAMENTS1 
 
 
 Respiratory viral infections are among the leading causes of medical care in 
the United States.  The most common respiratory viruses in humans are influenza 
virus, parainfluenza, metapneumavirus and respiratory syncytial virus (RSV).2, 3  
RSV, a paramyxovirus, is the leading cause of lower respiratory tract infections in 
infants and young children and results in an estimated 90,000 hospitalizations 
annually in children under five years of age.4-6 Worldwide, RSV is the cause of death 
of over 1 million children per year.7  Furthermore, RSV is problematic for elderly and 
immuno-compromised populations.8, 9   
 Recently, antivirals have been made available for treatment of RSV, but they 
are only effective when given in the early stages of infection, creating a need for 
early-stage diagnostics.10, 11  The importance of these diagnostic tests is further 
emphasized by the fact that there is no approved vaccine for RSV.12  Rapid, simple 
and accurate diagnostic tests for early respiratory virus infections would give 
physicians additional information and help avoid the use of unnecessary antibiotics 
which has led to soaring rates of antibiotic resistance in the U.S.13-16   
 Although a number of diagnostic alternatives exist, none of them are fast, easy 
and sensitive enough to be an attractive option in a clinical setting.  Viral infections 
are typically detected in clinical diagnostic labs using cell cultures, serology, or direct 
antigen detection, but each has a significant drawback.  Cell cultures usually require 
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expertise and extended observation time of up to ten days.  Serological methods, 
which detect antibodies in response to a viral infection, are difficult to interpret when 
diagnosing repetitive or chronic viral infections such as RSV.  Direct antigen 
detection, such as immunofluorescence, requires technical expertise in using a 
fluorescence microscope and is far from a simple diagnostic.17, 18 Alternatively, PCR 
and immuno-PCR have proven to be very sensitive diagnostics; however, they require 
technical expertise and often suffer from high false positive rates due to DNA 
contamination.19-21 
 From the clinical perspective, one of the most attractive features of a recently 
published antibody-based virus detection technology approach is the simplicity of 
sample processing.  This filament-based antibody recognition assay (FARA) utilizes 
an ELISA-like sandwich detection strategy that employs antibodies immobilized on a 
moveable polyester filament to capture antigen.22-24  The filament is then pulled 
through a series of capillary tubes to achieve assay processing and detection.  
Although FARA allows for rapid processing and detection, to date its sensitivity is 
comparable to ELISA, with a lower limit of detection of ~1.7 x 107 virus particles.22 
 In this work, the filament-based design is modified to incorporate the use of a 
gold-clad filament as a fluorescence quencher for molecular beacon hairpin structures 
coupled along the construct at known locations. Molecular beacon detection strategies 
have proven very successful for identifying a variety of DNA targets, ranging from 
pathogens25 and cancer cells26, 27 to single nucleotide polymorphisms.28  Molecular 
beacons are composed of single stranded DNA designed with 5´ and 3´ ends that are 
complementary to each other, ensuring that the beacon remains in a hairpin 
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conformation in the absence of target DNA.  One end of the beacon is functionalized 
with a fluorophore and the other with a quencher.  While the beacon is in a hairpin 
conformation, the fluorophore is spatially close to the quencher and fluorescence is 
not observed, rendering the beacon in a “dark” state.  In the presence of target DNA, 
however, the target anneals to the beacon, and the hairpin opens.  As a result, the two 
ends of the beacon are spatially separated, eliminating quenching, resulting in a 
“bright” signal state.  As shown in this report, the combination of molecular beacons 
with filament processing retains the simple and rapid processing design and improves 
the lower level of detection significantly.   
 
Experimental 
 
DNA Preparation and Immobilization on Filaments.  RSV hairpin DNA was 
purchased from Biosearch Technologies, the sequence of which can be found in Table 1 
(RSV Probe) and is discussed in Results and Discussion.  Gold-plated tungsten filament 
(100 µm diameter) was purchased from Luma Metall Fine Wire Products (Kalmar, 
Sweden).  6-Mercapto-1-hexanol was purchased from Aldrich chemical company.  All 
H2O used was Gibco ultraPURE DNAse RNAse Free.  The buffer used was 10 mM 
phosphate buffer with 0.3 M NaCl, pH 7.0 (PB). 
Thiolated probe DNA sequences were received as disulfides and were activated 
by cleaving the disulfide bond.  Cleavage was performed in 100 mM dithiothreitol 
(DTT), 0.1 M phosphate buffer, pH 8.3.  After 0.5 hr, thiolated DNA was purified using  
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Table 1.  Oligonucleotide sequences used in filament studies.  The underlined regions of the sequence 
indicate the “stem” which keeps the hairpin closed in the absence of target RNA.  CAL indicates the 
position of a CAL Fluor Red 590 dye which is a TAMRA equivalent.   
Name  Sequence 5´ → 3´ 
RSV Probe   [C6Thiol]TTTTTTTTTTCGACGAAAAATGGGGCAAATACGTCG[CAL]  
RSV Target   TTTTTTATTTGCCCCATTTTTTTTTT  
FemA Target   ACGCTCACTATGAGTTAAAGCTTGCTGAAGGTTATGA  
RSV Primer1   GCTCTTAGCAAAGTCAAGTTGAATGA  
RSV Primer2   TGCTCCGTTGGATGGTGTATT  
GAPDH Primer1   GGTGGTCTCCTCTGACTTC  
GAPDH Primer2   CTCTTCCTCTTGTGCTCTTG  
Linear Capture 
Probe  
[C6Thiol]TTTTTTTTTTTTTTTCTGTGTAAGCTTTGTCTT[Quasar 670] 
 Linear Target   [TAMRA]AAGACAAAGCTTACACAG 
Biotin Capture 
Probe  
[C6Thiol]TTTAAAAATGGGGCAAATA 
Biotin Target   [C6Biotin] TATTTGCCCCATTTTT 
 
 
Millipore Microcon YM-3 spin filters.  The purified DNA was diluted to 30 μM in H2O 
and stored in small aliquots at -80 °C.   
 Gold-plated filaments were cleaned by thorough rinsing in PB.  The cleaned 
gold filament was incubated overnight at room temperature in a solution of PB 
containing 1 μM of activated DNA and 10 μM mercaptohexanol.  After a minimum of 
8 hr, the filaments were removed from the DNA solution and rinsed with PB.  The 
filaments were then stored at 4˚C in PB until use. 
RSV Infection of HEp-2 Cells.  Uninfected HEp-2 cells were incubated at 37˚C 
with 5% CO2 and grown to 80% confluency in OPTI-MEM media containing 2% fetal 
bovine serum, 200 mM L-glutamine, 250 µg/ml of amphotericin-B and 10 mg/ml 
gentamicin (c/OPTI-MEM/2%).  Quick thawed virus diluted in c/OPTI-MEM/2% was 
used to infect 80% confluent HEp-2 cultures.  Following infection, flasks were incubated 
at 37°C, 5% CO2 for 4 days.   
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 Titer of Infected Cells.  An aliquot of infected cells was suspended in 1 mL 
c/OPTI-MEM/2% and used to determine the titer of the virus.  The 1 ml of stock was 
then frozen using a slurry of ethanol and dry ice. After freezing, the supernatant was 
thawed in a 37°C water bath. The freeze/thaw cycle was repeated three times to 
maximize the release of virus particles from the cell wall. After the third cycle, the 
supernatant was separated and used to infect three columns (18 wells) of a 24-well 
microtiter plate.  Each successive row of the column was infected with a 10-fold serial 
dilution of the stock.  After infection, the cells were incubated for 1 hr at 37°C and 5% 
CO2.  The cells were then overlaid with 1 mL of media containing 0.75% (w/v) 
methylcellulose and incubated for 4 days at 37°C and 5% CO2.   
After incubation, the cells were fixed with cold 80% methanol and stored at 4°C 
for at least 1 hr.  Cells were blocked with 2% BSA in Dulbeccos’ PBS (Mg2+ and Ca2+ 
free) for 1 hr.  After blocking, the cells were incubated for 30 min at room temperature 
with a 1:1000 dilution of anti-RSV F protein antibodies (final concentration of 20 
μg/mL).  The cells were then washed with PBS and incubated in a 1:1000 dilution of 
secondary antibody (goat anti-mouse horseradish peroxidase (HRP) conjugate, Santa 
Cruz Biotechnology) for 1 hr.  Excess antibody was removed by rinsing with PBS.  The 
HRP was then developed with a TrueBlue peroxidase precipitating substrate (KPL 
Protein Research Products) which rendered a colored dot.  The dots were then counted to 
quantify the amount of plaque forming units (PFU). 
 RNA Isolation from HEp-2 Cells.  Four days post-infection (for infected cells) or 
at 100% confluency (for uninfected cells), the cells were washed two times with PBS and 
then scraped from the flasks.  The scraped cells were centrifuged at 1500 x g for five min 
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to pellet the cells.  The supernatant was removed and RNA was extracted in 
approximately 30 min using a 5-Prime PerfectPure RNA Cell and Tissue kit.  Cells were 
lysed in lysis buffer and passed 10 times through a 22 gauge needle.  The cell lysate was 
passed through a spin filter to bind nucleic acids.  The filter was washed, treated with 
DNase and washed two more times.  Finally, the extracted RNA was eluted from the 
filter with H2O, and the concentration was obtained via UV-Vis Spectroscopy.   
RSV N-Gene RNA Standard.  E. coli transformed with the RSV N-gene cloned 
into a pcDNA3.1(-) vector was received from the Crowe Lab.  E. coli was grown 
overnight in Miller’s LB Broth at 37°C on a rotating rack.  The next day, growth was 
confirmed by the turbidity of the broth and the plasmid was extracted using a Qiagen 
Spin Miniprep Kit.  The concentration of extracted plasmid DNA was then calculated 
using UV-Vis spectroscopy.  The purified plasmid was linearized using a Pvu I restriction 
enzyme and linearization was confirmed by running both pre- and post-linearized 
plasmids on a 1% agarose gel.  Linearized plasmid was purified using ethanol 
precipitation.  The purified plasmid was then transcribed into RNA using a T7 
MEGAscript transcription kit.  Appropriate RNA length was confirmed on a denaturing 
Agarose-Formaldehyde gel.  The N-gene RNA was then quantified using UV-Vis 
spectroscopy, separated into aliquots, and stored at -80°C. 
 Viral RNA Hydrolysis.  Hydrolysis was performed by adding an equal volume of 
H2O to extracted RNA, followed by the addition of two volumes of carbonate buffer (pH 
10.2).  The RNA was then incubated at 65°C for up to 60 min, depending on the amount 
of desired hydrolysis.  In this experiment, samples were incubated for 0, 1, 5, 15, 30 and 
60 min.  After incubation, the hydrolysis was stopped with neutralization buffer (3 M 
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sodium acetate, 1% (v/v) acetic acid; pH 6.0).  Following neutralization, the hydrolyzed 
RNA was ethanol precipitated and finally, resuspended in H2O and stored at -85°C.  To 
verify hydrolysis, the hydrolyzed samples were run on an Agilent 2100 Bioanalyzer, and 
the resulting electropherograms were examined.  
RNA Capture and Detection.  Gold-clad filaments were functionalized, as 
described above, with molecular beacon style capture DNA.  The functionalized filament 
was then incubated for 2 hrs at room temperature in PB containing 3 ng/μL of total RNA 
extracted from RSV-infected and uninfected cells.  Following capture of the target RNA, 
the filament was washed for 1 min in 2X sodium citrate/sodium chloride (SSC), 1X SSC, 
0.1X SSC and finally in PB.  The filament was then mounted on a glass slide and imaged.  
Fluorescence measurements of the filament were performed on an Axon Instruments 
GenePix 4000B microarray scanner.  The scanner is equipped with excitation lasers of 
532 nm (green) and 635 nm (red), and 575DF35 and 670DF40 emission filters.  
Fluorescence was quantified using GenePix software.  Regions of interest (ROI) were 
created along the entire length of the filaments, and the ROIs were averaged to obtain the 
average fluorescence along the filament. 
Biotin-Streptavidin Amplification.  In a typical experiment, a 100 μm diameter 
gold filament was incubated overnight at room temperature in a solution of 10 mM 
phosphate buffer, pH 7.0 and 0.3 M NaCl (PB) containing 1 μM of activated DNA to 
couple the capture DNA to the filament.  Following DNA coupling the filament was 
washed for 5 minutes in phosphate buffered saline (PBS).  The filament was then 
incubated for 3 hours at room temperature in PB containing target DNA, which was the 
Watson-Crick complement of the capture strand functionalized with a 5´ Biotin.  
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Following capture of the target DNA, the filament was washed in 2X SSC, 1X SSC, 0.1X 
SSC and finally in PB.  The filament was then incubated for 1 hour in PBS containing 1 
nM streptavidin-Qdots, followed by washing in PBS for 5 minutes.  After the initial 
labeling, the filament was incubated for a 2nd hour in PBS containing 1 nM biotin-Qdots, 
followed by washing in PBS for 5 minutes.  Finally, the filament was incubated once 
again in 1 nM streptavidin-Qdots for 1 hour, followed by washing in PBS for 5 minutes.  
The filament was then mounted on a glass slide and imaged. 
Real-Time RT-PCR for PFU Quantitation of RNA Samples.  Real-time RT-PCR 
was performed using a SmartCycler II thermal cycler system (Cepheid, Sunnyvale, CA).  
Reactions were done in a 25 µL volume with 12.5 µL of 2X One-Step qRT-PCR Buffer 
plus SYBR (Clontech), 0.5 µL of 50X QTaq DNA Polymerase Mix (Clontech), 0.4 µL of 
60X qRT Mix (Clontech), 200 nM left and right primers (RSV or GAPDH primers, 
Table 1), and H2O.  The protocol consisted of RT followed by a three-step PCR.  RT was 
performed at 48°C for 20 min followed by an initial QTaq DNA polymerase activation 
step of 95°C for 3 min and 40 cycles at 95°C for 15 sec to denature, 60°C for 60 sec to 
anneal and extend, and 72°C for 15 sec to detect fluorescence. 
ELISA.  A standard indirect sandwich ELISA was performed.29  A stock solution 
of RSV infected HEp-2 cell lysate (3.0x104 PFU/mL) was serially diluted 1:2 and used to 
determine the lower limit of detection.  To allow capture antibodies to bind to the 
Immulon 2HB microtiter plate, 100 μL of 2 μg/mL F-mix (an equal mixture of two anti-
RSV fusion protein antibodies, clones 1269 and 1214) was added to three rows of the 96-
well plate and placed in a humidified box at room temperature for 1 hr.  After 1 hr, the 
wells were rinsed three times with PBS and blocked with 2% BSA for 10 min.  After 
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blocking, BSA was removed from the wells and 100 μL of infected cell lysate stock was 
placed in the three rows of column 1 and serial dilutions in columns 2 through 11, leaving 
column 12 for PBS.  The plate was then placed back in a humidified box at room 
temperature for 1 hr.  Following antigen binding, the wells were rinsed three times with 
PBS and 100 μL of 10 μg/mL of primary antibody (Synagis, humanized monoclonal 
antibody, MedImmune Inc.) was added to each well.  The plate was placed in a 
humidified box at room temperature for 1 hr.  The wells were then rinsed three times with 
PBS and 100 μL of secondary antibody (1:1000 dilution of goat anti-human HRP 
conjugated, Pierce) was added to each well.  After 1 hr in a humidified box at room 
temperature, the wells were rinsed five times with PBS.  Next, 100 μL of substrate 
(Tetramethylbenzidine, Pierce) was added to each well and the enzymatic reaction was 
allowed to proceed for 10 min, after which it was quenched with 100 μL 2 M H2SO4.  
Finally, absorbance at 450 nm was measured using a Bio-Tek Synergy HT microplate 
reader.  
 
Results and Discussion 
 
The following viral detection design utilizes a molecular beacon-style hairpin 
DNA covalently coupled to a moveable gold-clad filament (Figure 8).  This allows 
the viral probes attached to the filament to be easily added to and removed from 
processing solutions.  In adapting molecular beacons for use with the simple 
processing offered by FARA, the quenching function is performed by the gold-clad 
filament itself.  Studies have shown that fluorophores in close proximity to metal  
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Figure 8.  Illustration of the filament-based assay method.  In an analyte solution, a conformational 
change is observed when the molecular beacon style probe DNA binds target DNA/RNA.  In the closed 
conformation (negative), the fluorophore is in close proximity to the gold surface and is quenched.  Upon 
binding the target (positive), the fluorophore becomes spatially separated from the gold surface.  After 
binding the target, the filaments are rinsed and mounted to a glass slide for imaging.  Upon excitation at the 
desired wavelength (532 nm), fluorophores that have bound target and are in an open conformation will 
exhibit a distinct fluorescence signal (575nm). 
 
surfaces can experience changes in emission intensity.30, 31  Specifically, metal 
surfaces have been shown to quench a beacon while it is in a hairpin conformation.32-
35  This quenching effect is typically only observed at fluorophore to metal distances 
of ≤ 5-10 nm which is on the scale of Förster energy transfer processes.31, 35  By using 
a metal filament for probe DNA attachment, the metal filament can be used as a 
quencher for the beacon in the closed state. 
 DNA Coupling to Gold Filaments.  The first step in the successful 
development of this new diagnostic approach was to examine the appropriate 
coupling conditions for covalent attachment of DNA to the gold filament.  These 
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studies utilized a short linear 55-mer oligonucleotide functionalized with a 5´ thiol 
and a 3´ fluorescent dye (Linear Capture Probe, Table 1).  In order to determine the 
optimum time for coupling, a series of experiments were perform exposing 50 μm 
diameter gold-plated tungsten filaments to activated DNA for 1 to 16 hr.  The images 
from the time-dependence study (Figure 9) revealed significant coupling as early as 4 
hr.  At 4 hr, 78% of the maximum fluorescence was obtained and after 8 hr, ≥90% of 
maximum fluorescence was obtained.  Using this information, 8 hr was chosen as a 
minimum time to facilitate optimal coverage of filament in subsequent experiments. 
 
 
Figure 9.  Time dependence of coupling.  Fluorescence scan of gold-plated filaments with Quasar 670-
tagged capture DNA.  All wire were coupled using a solution of 5 μM capture DNA with differing coupling 
times, ranging from 1 hour to 16 hours.  The greatest coupling occurs after 16 hours, but sufficient coupling 
has occurred after 4 hours. 
 
 
In order to show that the coupling of DNA to the filament did not prevent 
hybridization of complementary DNA in solution, two types of DNA were employed.  
The capture DNA was functionalized with a 5´ thiol and a 3´ Quasar (670 nm) dye 
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bind to the gold filament, instead it is washed away unless it is hybridized to a thiol-
coupled strand. 
 Biotin-Streptavidin Signal Amplification.  Although the ultimate goal of this work 
was to utilize molecular beacon structures on gold filaments, the use of linear DNA does 
allow for unique amplification strategies.  One promising amplification method was 
based on the exposure of hybridized DNA containing a 5´ biotin to successive rounds of 
streptavidin quantum dots and biotin quantum dots (Figure 11). In a test of this approach, 
a filament functionalized with capture DNA (Biotin Capture Probe, Table 1) was 
incubated with biotinylated target DNA (Biotin Target, Table 1) for 3 hours at room  
 
 
Figure 11.  Illustration of Biotin-Streptavidin amplification.  After the capture of biotinylated target 
DNA, the filament is incubated with streptavidin Qdots.  After washing, the filament is then incubated in 
biotinylated Qdots.  This process can be repeated multiple times for additional amplification.  
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temperature.  Following capture of the target DNA, the filament was washed and then 
incubated in PBS containing streptavidin-Qdots. After the initial labeling, the filament 
was washed and then incubated in PBS containing biotin-Qdots. Finally, the filament was 
washed and then incubated once again in streptavidin-Qdots. The filament was then 
washed, mounted on a glass slide and imaged. The resulting amplification of binding 
signal using biotin and streptavidin quantum dots can be seen in Figure 12. The average 
fluorescence of the three wires was 400 (left wire, not visible), 2400 (center), and 5800 
(right) relative fluorescence units, suggesting that successive rounds of incubation in 
Qdots does result in signal amplification. 
 
 
Figure 12.  Amplification of binding signal using biotin and streptavidin quantum dots. A) The 
average fluorescence of the three wires.  B) The difference in fluorescence is also clearly visible in 
fluorescence scan. 
 
Hairpin DNA Design.  The sequence of hairpin DNA used in this study to 
target RSV viral RNA is shown in Figure 13.  The RSV specific probe is designed so  
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Figure 13.  RSV Probe DNA’s hairpin and linear conformations.  In the absence of target DNA, RSV 
probe DNA is in a hairpin conformation (top), bring both the 5´ and the 3´ ends in close proximity to one 
another.  However, the presence of target DNA disrupts the hairpin conformation (bottom).  
 
that the initial loop region targets a gene end-intergenic start sequence which has 
three exact repeats and six almost-exact repeats with various numbers of nucleotide 
mismatches throughout the RSV genome.36, 37  Similar intergenic repeats are common 
in other RNA viruses,38 suggesting that the approach may be generalized to the study 
of other viruses. Successfully used in antisense and small interfering RNA 
experiments,37-39 this site was considered the most accessible and therefore, a prime 
site for oligonucleotide binding and probe targeting.  As shown in Figure 13, this 
RSV specific sequence is then flanked by five base stem regions that hold the DNA in 
a closed conformation in the absence of RSV RNA.  The 5´ end of the hairpin is 
further functionalized with a 10-base poly-T linker.  Of the four possible nucleotides, 
thymines are the least reactive with gold surfaces.40  This sequence promotes 
favorable orientation and binding of the DNA through the 5´ thiol with minimal 
adsorption to the surface.  Additionally, the 3´ end of the hairpin is functionalized 
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with a TAMRA equivalent dye to facilitate detection.  Prior to RNA binding, the stem 
region of the probe ensures that the DNA maintains a hairpin conformation.  Upon 
binding of viral RNA, the probe undergoes a conformational change that increases the 
distance between the fluorophore and the gold-clad filament which results in an 
increased fluorescence signal (Figure 8). 
Effect of Probe Density on Signal-to-Noise.  Initial studies indicated that the gold 
surface quenches the 3´ hairpin fluorophore when the hairpin is in a closed state and that 
this quenching is dependent on probe density at the gold surface.  Gold-clad filaments 
were functionalized with various molar ratios (1:0 to 1:20) of RSV probe DNA and 
mercaptohexanol.  The mercaptohexanol competes with the probe DNA for binding at the 
gold surface, separating DNA beacons at higher molar ratios of mercaptohexanol.  After 
being functionalized, half of the filaments were imaged to gather information about the 
dark state at each of the molar ratios.  The other half of the filaments were incubated with 
100 nM RSV target DNA to open the hairpin probes and then imaged for information 
about the bright state at each of the molar ratios.  Fluorescence data from both the dark 
and bright states was then used to calculate the signal-to-noise ratio for each of the 
conditions (Figure 14).  These results were then used to optimize the probe density along 
the filament for all subsequent experiments. 
 At low concentrations of mercaptohexanol (1:0, 1:2 and 1:5), the signal-to-noise 
is low due to the lack of quenching in the dark state.  At these concentrations, the 
monolayer is principally composed of probe DNA.  At this attachment density, the DNA 
strands are too close together to fold into the hairpin conformation, thus resulting in 
substantial fluorescence in the dark state.  In higher mercaptohexanol concentrations  
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Figure 14.  Effect of probe spacing on fluorescence.  Comparison of the signal–to-noise ratio of 
filaments functionalized with mixed monolayers of RSV probe DNA and mercaptohexanol. 
 
(1:10), the DNA strands have sufficient room to fold into the hairpin conformation, 
resulting in adequate quenching and a substantially higher signal-to-noise ratio.  At the 
highest mercaptohexanol concentration tested (1:20), the noise no longer decreased as the 
DNA had sufficient room to adopt the hairpin conformation.  Additionally, the signal-to-
noise ratio was reduced due to a lower density of probe DNA on the gold surface. 
Specificity of Filament-Based Detection.  The specificity of the RSV-targeted 
filament was examined against positive (RSV) and negative (femA) control complements 
(Table 1).  RSV target DNA is the synthetic DNA equivalent of the RSV RNA targeted 
by the RSV probe.  The femA sequence, a portion of the femA gene33 which encodes a 
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protein whose expression is necessary for methicillin resistance in Staphylococcus 
aureus, was selected to be a biologically significant probe with a similar GC content to 
that of the RSV target.   
 As Figure 15 illustrates, hairpin opening due to target capture was highly 
dependent on the sequence of the target DNA in solution.  To test this, filaments 
functionalized with RSV specific probe DNA were incubated with various 
concentrations of either RSV target DNA or femA target DNA (Table 1), ranging  
 
 
Figure 15.  Specificity of probe functionalized filaments.  Comparison of filament-functionalized RSV 
probes in the presence of increasing concentrations of RSV target DNA and nonspecific femA target DNA. 
 
from 1 fM to 100 nM.  At femtomolar concentrations of femA target DNA, the 
filaments functionalized with RSV probes remain primarily in the dark state.  At high 
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nanomolar concentrations of femA, probes begin to open slightly, but this signal is 
still below a 5σ limit of detection and significantly less than the signal generated by 
the RSV probes at 1 fM RSV target DNA.  It is apparent that concentrations greater 
than 100 nM femA target DNA, can force nonspecific interactions; however, across 
the range of concentrations tested, the signal was significantly higher in RSV target 
DNA than in the nonspecific femA target DNA. 
 Detection of Viral RNA.  As expected, RSV-targeted filaments detect viral RNA 
isolated from infected cells.  This was demonstrated using functionalized gold-clad 
filaments incubated in capillaries with 20 uL of RNA (3 ng/μL) from either uninfected or 
RSV infected HEp-2 cells.  As seen in Figure 16, the filament-coupled DNA probes have 
two states: a dark state corresponding to a probe that remains in a closed conformation  
 
 
Figure 16.  Response of probe DNA upon target binding. A) The average fluorescence along filaments 
functionalized with RSV probe DNA that have been exposed to lysates from either uninfected HEp-2 cells 
(left) or RSV infected cells (right).  B) An image of these same filaments. 
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and a bright state corresponding to a probe that has captured viral RNA.  The high 
quenching efficiency for the closed state allows for ease of detection when comparing 
uninfected cells (1,006 RFU) to RSV-infected cells (28,325 RFU).  Using the average 
fluorescence values along the entire length of the filaments, the quenching efficiency of 
the gold filament for probe DNA in a hairpin conformation was found to be ~97%.   
Optimum Length of Target RNA.  The genomic sequence targeted was selected 
because it is not only specific to RSV but also repeated throughout the genome.  
Therefore, hydrolyzing the RSV into smaller fragments would make the repeated sites 
more available for capture by probe DNA and improve capture efficiency.41  As 
expected, the changes in the RNA lengths confirm an increase in hydrolysis over time 
when measured by an Agilent bioanalyzer (Figure 17A).  Signal increased to 2.5-fold of  
 
Figure 17.  Effect of target RNA length on detection. A)  Electropherogram verifying the hydrolysis of 
RNA at each of the time points.  B) Average fluorescence and an image showing the effect of target RNA 
length on the resulting signal.  At fifteen minutes the highest signal was observed. 
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full length genomic RNA after 15 min of hydrolysis (Figure 17B).  These results indicate 
that short hydrolysis times result in decreased viral RNA lengths, making the target easier 
to capture and also increasing the number of target sites available for capture.  However, 
with hydrolysis times greater than 30 min, these benefits are overcome by degradation of 
target sequences. 
 Standardization of the Beacon-Filament Assay.  In order to compare these 
results to other diagnostics, such as ELISA, a portion of each sample was used to 
determine the number of PFUs in that sample.  This conversion from RNA 
concentration to PFU was done using real-time RT-PCR (reverse transcription-  
 
Figure 18.  Conversion of delta Ct to PFU.  Standard curve with an R2 of 0.991 relating the delta Ct of 
RSV and GAPDH RNA to PFU.  
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polymerase chain reaction) to generate a standard curve relating delta (Δ) cycle 
threshold (Ct) of RSV RNA and GAPDH RNA to PFU.  In PCR based RSV 
diagnostics, GAPDH has been shown to be a potential internal control when 
comparing samples.  Therefore, samples of known PFU were processed using real 
time RT-PCR to determine the Ct with either RSV specific primers or GAPDH 
specific primers.  The GAPDH Ct was then subtracted from the RSV Ct to calculate 
the ΔCt of the sample.  When plotted against the log10 of PFU, a simple linear 
relationship was determined (Figure 18).  This linear relationship was then used to 
calculate the PFU of unknown samples using only the ΔCt of the sample.   
 
Figure 19.  N-Gene copy number versus Cycle Threshold.  Standard curve with an R2 of 0.9952 relating 
Ct to the Log10 transformed number of copies of RSV RNA.  
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Additionally, stock of a known concentration of RSV N-gene RNA was used 
to calculate the number of RNA copies in the RSV samples.  The RNA stock was 
serially diluted over 7-orders of magnitude and analyzed via RT-PCR.  The dilutions 
allowed for the generate of a standard curve relating cycle threshold to the Log10 of 
copies of N-gene RNA (Figure 19).  The curve was then used to calculate the number 
of RNA copies in each of the RSV samples tested with the beacon-filaments. 
Beacon-Filament Limit of Detection.  The beacon-filament lower limit of 
detection was approximately 200 times lower than a comparison ELISA.  Filaments 
 
 
Figure 20.  Comparison of the RSV detection using ELISA or the developed filament-based assay.  
The limit of detection using ELISA was 1750 PFU while the filament had a limit of detection of 11.9 PFU. 
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were incubated in solutions containing increasing amount of RNA isolated from RSV 
infected cells while keeping the concentration of total RNA constant at 3 ng/μL.  The 
amount of the RNA isolated from RSV infected cells ranged from RNA isolated from 
uninfected cells (0 ng/μL), to that isolated from infected cells (3 ng/μL).  Real-time RT-
PCR was then used to convert the nanograms of RNA from infected cells to PFU.  
Figure 20 compares the limit of detection of the filament-based assay and ELISA.  Using 
a 5σ limit of detection, the filament-based assay was able to detect as few as 11.9 PFU 
while the limit of detection for ELISA was 1750 PFU.  Using real-time RT-PCR and a 
stock of RSV-N gene of a known concentration, the 11.9 PFU limit of detection was 
calculated to be equivalent to ~5000 copies of genomic RSV viral RNA in 20 μL.  This  
 
 
Figure 21.  Linear range of the filament-based assay.  A linear range up to 115 PFU can be calculated 
with an R2 of 0.9717. 
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corresponds to a limit of detection of 4.15 x 10-16 M (~400 aM) RSV viral RNA.  
Additionally, the linear range of the filament assay was reliable up to 115 PFU (R2 = 
0.97) after which, the signal generated from the filaments saturated (Figure 21). 
 
Conclusions 
 
 DNA functionalized gold-clad filaments responded only to RSV RNA, even in 
high concentrations of cellular RNA from uninfected HEp-2 cells.  Although these 
studies focused on the detection of viral RNA from cultured cells, ongoing research is 
exploring the functionality of the filaments in clinical samples.  These samples, 
nasopharyngeal aspirates from RSV infected children, will further demonstrate the 
clinical utility of the DNA functionalized filaments.  The filament assays represent a 
core technology that has the potential to be much simpler than ELISAs, requiring only 
movement from one capillary to another, whereas an ELISA requires pipetting, 
washing, blocking and enzymes to develop the signal.  Additionally, the filaments 
proved to be much more sensitive than ELISA, detecting as few as 12 PFU.  Both the 
sensitivity and simplicity of DNA functionalized filaments make them a promising 
alternative in the development of an improved clinical diagnostic. 
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CHAPTER III 
 
DETECTION OF RESPIRATORY SYNCYTIAL VIRUS USING NANOPARTICLE 
AMPLIFIED IMMUNO-PCR 
 
 
The most important cause of severe respiratory illness in young children and 
infants is respiratory syncytial virus (RSV).  RSV is the major cause of infantile 
bronchiolitis and the most frequent cause of hospitalization of infants and young children 
in industrialized countries.1  In the United States, RSV is estimated to account for over 
125,000 infant hospitalizations for bronchiolitis or pneumonia per year.2  Although not 
fatal to the majority of patients, RSV can be deadly in immuno-compromised 
populations, and in the U.S., RSV is responsible for 10,000 deaths annually in patients 
over the age of 65.3, 4  Additionally, naturally acquired immunity to RSV is not complete, 
and recurrent infection can be frequent.5-7 
 Early attempts at developing a formalin-inactivated RSV vaccine were hindered 
by an increase in disease severity upon subsequent infection of vaccinated patients.8-10  
Because of such problems, there is no approved vaccine for RSV.11  Without a vaccine, 
treatment is typically limited to prophylactic passive immunization with neutralizing 
humanized monoclonal antibodies (palivizumab) or antivirals (ribavirin).5, 12  The cost 
associated with monthly prophylactic passive immunization is expensive, so it typically is 
only utilized in premature or other high-risk infants.12, 13  Additionally, these prophylactic 
treatments have been associated with adverse outcomes in infants with cyanotic cardiac 
disease.5  Another option, antivirals, is only effective when used early in the course of 
infection, making early detection crucial.14 
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Although a median infective dose (ID50) for RSV has not been established in 
humans, one clinical study showed that as few as 120 to 440 plaque forming units (PFU) 
in two milliliters of Hank’s balance salt solution caused an infection in 83% of healthy 
adult volunteers.15, 16  Another study using a temperature sensitive mutant RSV vaccine 
infected children with a dose as low as 27 PFU.17  These are likely overestimates since as 
the RSV strain is passaged in laboratory culture, it is thought to become attenuated and 
that the dose of wild RSV actually required to infect an infant likely is even less than 20 
PFU.18 
With the knowledge that treatment is most effective early in the course of an 
infection, and that even relatively few PFUs can result in infection, it is clear that 
sensitive diagnostics for RSV are essential for effective treatment.  Current methods for 
the detection of RSV include cell culture, serology and direct antigen detection.  Each of 
these has limitations.  Cell culture methods are hindered by extended observation times of 
up to ten days and required expertise.19, 20  Serology based methods, which look for 
antibodies in response to an infection, are difficult to interpret when dealing with 
reoccurring infections.  Many direct antigen detection strategies suffer from a lack of 
sensitivity; and those that are highly sensitive, such as nanoparticle magnetic resonance 
imaging, usually require additional, often expensive, equipment that is not typically 
present in a clinical setting.21   
Direct antigen detection which detects the virus, or at least a specific protein on 
the virus, are often not sensitive enough to detect the early stages of infection where viral 
titers are expected to be low.22  Enzyme-linked immunosorbent assays (ELISA) are an 
example of a rather insensitive direct antigen detection diagnostic.23  However, ELISAs 
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are still common tools because of their simplicity in sample preparation and processing.  
Immuno-Polymerase Chain Reaction (I-PCR) offers processing similar to ELISA while 
coupling the sensitivity of PCR.24  Additionally, the equipment and expertise to perform 
both ELISA and PCR are typically available in clinical laboratories. 
To date, one of the most sensitive diagnostics available for the detection of RSV 
has been the use of RT-PCR to amplify and detect RSV genetic material.25, 26  However, 
detection of the negative-sense RNA genome or mRNA of the virus comes with a few 
drawbacks.  First, RNA is very sensitive to degradation by RNases and typically has a 
shorter half-life than proteins.27, 28  This, in turn, places increased importance on 
preparation, pre-assay handling and storage of samples for RT-PCR diagnostics.29  
Secondly, studies have shown that RSV mRNA expressed during infection is cyclical and 
can limit the amount of mRNA present to detect at any given time; however, the surface 
fusion protein (F-protein) increases monotonically over time.30  Further, the link between 
RT-PCR viral load and disease severity has yet to be established.26  In contrast, an I-PCR 
based diagnostic for the detection of RSV comes with two inherent strengths.  First, 
empty viral nucleocapsids can be detected because only the presence of a specific protein 
is required for a positive result.31  Even fragments of cell wall that have the protein of 
interest expressed can be detected.  Secondly, each virion contains only a single copy of 
RSV genomic RNA, but the protein targets are often expressed at a higher copy number, 
each one of which can act as a potential target.32 
I-PCR has been modified in a number of ways to strengthen various aspects of the 
assay.  Different antibody-DNA linking strategies have been used; from streptavidin-
protein A coupling, to strictly streptavidin-biotin coupling, and even phage display 
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mediated I-PCR (PD-IPCR), where a single chain variable fragments are displayed on the 
phage and phage DNA itself acts as a DNA tag.24, 32-34  Capture antibodies have been 
bound to biogenic magnetosome nanoparticles (M-IPCR)  instead of protein binding 
plates to enhance signal generation.35  Biotinylated DNA-streptavidin nanostructures 
have been used to increase the valency of the antibody binding, and in turn increase the 
sensitivity of I-PCR.36  However, these studies utilized an average DNA/complex ratio of 
only 5, as increased DNA ratios resulted in instability of the streptavidin conjugates.36  
An I-PCR related method, the bio-barcode assay, has even been developed which utilizes 
nanoparticles as a scaffold to attach multiple DNA tags per antibody construct and avoids 
the use of PCR amplification altogether.37   
In this work, we developed a Nanoparticle Amplified Immuno-PCR (NPA-
IPCR) assay for the detection of RSV (Figure 22).  The diagnostic assay offers 
amplification through two means to improve the limit of detection of a traditional 
ELISA.  Amplification of signal is achieved both by using multivalent gold 
nanoparticles (AuNPs) to release multiple strands of DNA per binding event and 
through the use of real-time PCR to amplify released DNA.  Additionally, the assay 
utilizes magnetic microparticles (MMPs) to capture antigen for improved washing to 
enable better target extraction.  Our results suggest that the NPA-IPCR assay not only 
offers >1000-fold improvement in limit of detection over ELISA, but also a 4-fold 
improvement over detection via real-time RT-PCR.  
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Experimental 
 
Coupling of Antibodies to Magnetic Microparticles.  MagnaBind™ amine 
derivatized 1 μm magnetic microparticles (product #21352, Pierce Biotechnology) were 
activated with sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate 
(Sulfo-SMCC).  In a typical reaction, 200 μL of MMPs were washed three times with 
coupling buffer (CB) consisting of 50 mM phosphate buffer (pH 7.0), 0.15 M NaCl and 5 
mM EDTA.  The MMPs were then cleared from the suspension using a magnet.  After 1 
min, the solution became clear and MMPs were pulled to the side of the tube. When the 
clear supernatant and the external magnetic field were removed, the MMPs were 
resuspended in CB.  After washing, the MMPS were activated with 20 μL of 1 mM 
Sulfo-SMCC. The solution was mixed and allowed to sit at room temperature for 1 hr. 
The MMPs were then washed 3 times to remove excess Sulfo-SMCC.  
Antibody reduction was coordinated so that once the MMPs were activated, they 
could be immediately used. Dithiothreitol (DTT) was used to reduce anti-RSV fusion 
protein antibodies (clones 1269 and 1214).  15 μL of 1.2 mM DTT was added to 15 μL of 
purified antibodies at 30 mg/mL in phosphate buffered saline (PBS). The solution was 
mixed and allowed to sit at room temperature for 0.5 hr. After that time, the antibodies 
were separated from DTT using a NAP-5 column (product #17-0853-01, GE Healthcare 
Bio-Sciences Corp.).  The activated MMPs were combined with the column-purified 
reduced antibodies and allowed to react for 1 hr at room temperature. The conjugation 
was quenched by the addition of β-mercaptoethanol to a final concentration of 100 μM.  
55 
 
After 1 hr quenching, the MMPs were washed three times with PBS and then 
resuspended in a final volume of 300 μL. 
Coupling of Antibodies and DNA to Gold Nanoparticles.  Thiolated DNA 
sequences (Biosearch Technologies) were received as disulfides and were activated by 
cleaving the disulfide bond. Cleavage was performed in 100 mM DTT, 0.1 M phosphate 
buffer, pH 8.3. After 0.5 hr, thiolated DNA was desalted using Microcon YM-3 
centrifugal filters (product #4410, Millipore). The purified DNA was resuspended in TE 
buffer and stored in small aliquots at -80°C.  
In a typical reaction, 35 μL of 0.2 mg/mL Synagis® antibody (humanized 
monoclonal antibody known to target the A antigenic site of RSV's fusion protein, 
product #NDC 60574-4114-1, MedImmune, Inc.) were added to 10 mL of 2.3 nM, 15 nm 
diameter AuNPs (product #15704-1, Ted Pella) at pH 9.3 and placed on a rotator for 0.5 
hr. 
Then, 50.8 μL of 107 μM activated DNA (Comp_55, Table 2) was added; the 
AuNPs were then rotated for another 0.5 hr. The solution was brought to 0.1 M NaCl, 10 
mM phosphate buffer, and 0.02% Tween20 and allowed to sit for 1 hr. After this time, 
the concentration of NaCl was brought to 0.2 M and to 0.3 M after a third hour. Excess 
DNA was removed by centrifuging the solution for 20 minutes at 21,100 x gravity. The 
clear supernatant was then removed, and the red oily pellet was resuspended in a stock 
solution of 0.3 M NaCl, 10 mM phosphate buffer and 0.02% Tween20 (PB). This 
washing process was repeated three times. After washing, particles were resuspended, 
and Tag DNA (Tag_76, Table 2) was added to bring the molar ratio of Tag DNA:AuNPs  
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Table 2. Oligonucleotide sequences used in NPA-IPCR studies. 
Name  Sequence 5´ → 3´ 
Comp_55  
[C6Thiol]TTTTTTTTTTTTTTTGCTTGTCTCGTAAGTTGAGATTTCGCTATGCA
CGGTCCTT  
Tag_76  
CTGCGACGATCTACCATCGACGTACCAGGTCGGTTGAAGGACCGTGCATAGC
GAAATCTCAACTTACGAGACAAGC  
Tag Primer 1   CTGCGACGATCTACCAT  
Tag Primer 2   GCTTGTCTCGTAAGTTGA  
RSV Primer 1   GCTCTTAGCAAAGTCAAGTTGAATGA  
RSV Primer 2   TGCTCCGTTGGATGGTGTATT  
 
to 200:1.  The solution was allowed to sit at room temperature overnight. Finally, excess 
Tag DNA was removed using the washing method described above.  
Preparation of RSV Infected Cell Lysate.  HEp-2 cells (product #CCL-23, 
American Type Culture Collection) were cultured in OPTI-MEM media supplemented 
with 2% fetal bovine serum, 250 µg/mL of amphotericin-B, 10 mg/mL gentamicin and 
200 mM L-glutamine and incubated at 37˚C with 5% CO2.  RSV stock was prepared by 
infecting a confluent T-150 flask of HEp-2 cells with RSV strain A2.  Infection was 
performed with rapidly thawed virus diluted to 5 mL in cell media.  Following the initial 
infections, cells were incubated for 1 hr after which 35 mL of cell media was added to the 
flask.  The infection was allowed to proceed for 4 days, after which cells were scraped 
from the surface of the T-150 flask. The supernatant containing the cells was collected in 
a 50 mL centrifuge tube and centrifuged for 5 min at 500 x gravity.  Following removal 
of the supernatant, the cell pellet was resuspended to 5 mL in cell media.  The cells were 
then frozen using a slurry of ethanol and dry ice in order to lyse cells and release virus 
particles. After freezing, the cells were thawed in a 37 °C water bath. The 
freezing/thawing cycle was repeated three times to ensure the release of virus particles 
from the cell wall. After the third cycle, the cells were centrifuged at 100 x gravity for 5 
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min to pellet large cellular debris.  The supernatant was then separated into aliquots of 
0.5 mL and stored at -80°C.  
Antibody-Magnetic Microparticle Characterization Experiment.  Pulldown 
experiments were performed to validate the attachment of antibodies to magnetic 
microparticles (MMPs).  10 μL of antibody-conjugated MMPs, 100 μL of a stock 
solution of RSV (1.675x10
6 
PFU/mL) and 100 μL 4% bovine serum albumin (BSA, 
product #A3059-100G, Sigma) were mixed and placed on a rotator for 2 hr. Unbound 
virus was then removed from the MMPs by cleaning as previously described in the 
antibody-MMP coupling reaction; this was done three times. Next, the MMPs were 
mixed with 100 μL of 2% BSA containing 12 μg/mL of F-mix antibody with a 655 nm 
quantum dot (QD) attached to the antibody.  The solution was stirred and placed on a 
rotator for 2 hr; unbound quantum dot-coupled antibodies were removed by cleaning the 
beads three times. After cleaning, the MMP-RSV-QD complexes were placed in a 96-
well plate on a BioMag® 96-well Plate Side Pull Magnetic Separator (product #85072, 
Polysciences, Inc.) and imaged on a Zeiss Axiovert 200 inverted fluorescence 
microscope. 
Validation of DNA-Gold Nanoparticle Functionalization.  Antibodies and 
activated DNA (Comp_55, Table 2) were attached to AuNPs following the procedure 
stated above.  After the removal of excess activated DNA, Tag DNA (Tag_76, Table 2) 
was added to the AuNPs. As a control, Tag DNA was also added to PB without AuNPs. 
The amount of complementary DNA added to 100 μL of AuNPs or PB was varied to 
determine the optimal molar ratio of Tag DNA:AuNPs for hybridization. After sitting at 
room temperature for 24 hr, the solution was centrifuged for 0.5 hr at 16,100 x gravity to 
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pellet the AuNPs and Tag DNA hybridized to them.  90 μL of supernatant was removed 
from both AuNP and PB samples.  The absorbance at 260 nm of the supernatant was then 
obtained on an Agilent 8453 UV-Vis spectrophotometer to determine the difference 
between samples incubated with and without AuNPs.  
To verify the release of Tag DNA upon heating, antibody-CompDNA-AuNPs 
prior to Tag DNA hybridization and post Tag DNA hybridization were compared.  
Samples were heated to 95ºC for 10 min then centrifuged at 21,100 x gravity for 15 min.  
The supernatant was then examined by measuring the absorbance at 260 and 280 nm.   
Quartz Crystal Microbalance Validation of Antibody-Gold Nanoparticle 
Attachment.  All quartz crystal microbalance (QCM) experiments were performed on a 
Maxtek, Inc. Research Quartz Crystal Microbalance with a flow rate of 30 μL/min. The 
crystals used were 5 MHz Ti/Au quartz crystals. After equilibrating for 0.5 hr in PBS, a 5 
minute PBS baseline was obtained. A RSV stock solution containing 4.0x10
5 
PFU/mL 
was then flowed over the crystal for 10 min, followed by an additional five minutes of 
PBS. After RSV binding, non-specific binding was blocked using a 1% BSA solution 
flow over the crystal for 10 min followed by 10 min of PBS. At this point, the flow was 
switched to either AuNPs functionalized with anti-RSV antibodies and DNA or, as a 
control, AuNPs functionalized with DNA alone.  
Nanoparticle Amplified Immuno-PCR (NPA-IPCR).  Pulldown experiments used 
5 μL of antibody-conjugated MMPs, 100 μL of infected cell lysate at the desired dilution 
and 200 μL of 5% BSA.  A stock solution of RSV infected HEp-2 cell lysate (8.33x106 
PFU/mL) was serially diluted 10-fold to determine the lower limit of detection.  The 
MMPs, virus, and BSA solution were mixed and placed on a rotator for 1 hr. Unbound 
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virus was then removed from the MMPs by cleaning as previously described. After three 
washes, the MMPs were mixed with 5 μL of 5 nM antibody-DNA functionalized AuNPs 
and 300 μL of 5% BSA and placed back on the rotator for 1 hr. The MMPs were then 
washed two times in 5% BSA followed by three additional washes in PBS. After the final 
wash, MMPs were resuspended in 300 μL of nuclease-free water. Solutions were then 
held at 95°C for 10 min followed by placement in an external magnetic field and removal 
of 100 μL of supernatant. The supernatant was then analyzed via PCR.  
Real-time PCR was performed using a Rotor-Gene Q 5-Plex thermal cycler 
system (Qiagen, Alameda, CA).  Reactions were done in a 25 µL volume with 12.5 µL of 
2X Rotor-Gene SYBR Green PCR Master Mix (product #204074, Qiagen), 200 nM left 
and right primers (Tag primers, Table 2), nuclease-free water and 5 µL of sample.  DNA 
polymerase activation was performed 95°C for 3 min and 40 cycles of 95°C for 15 sec to 
denature, 60°C for 60 sec to anneal and extend, and 72°C for 15 sec to detect 
fluorescence.  Following amplification, a melt curve from 50°C to 99°C was performed.  
The limit of detection was then determined using the assay’s linear range to calculate 3 
standard deviations above background. 
ELISA.  To allow capture antibodies to bind to the Costar UV microtiter plate 
(product #3635, Corning), 100 μL of 10 μg/mL F-mix antibodies were added the 96-well 
plate and allowed to incubate at room temperature for 1 hr.  After 1 hr, the wells were 
rinsed 3 times with PBS and blocked with 5% BSA in PBS for 1 hr.  A stock solution of 
RSV infected HEp-2 cell lysate (8.33x106 PFU/mL) was serially diluted 3-fold to 
determine the lower limit of detection.  Following blocking, BSA was removed from the 
wells and 100 μL of infected cell lysate at the desired dilution was added.  The plate was 
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then incubated at room temperature for 1 hr.  Following antigen binding, the wells were 
rinsed 3 times with PBS and 100 μL of 10 μg/mL of Synagis antibodies diluted in 5% 
BSA were added to each well.  Once again, the plate was incubated at room temperature 
for 1 hr.  The wells were then rinsed 3 times with PBS and 100 μL of a 1:1000 dilution in 
5% BSA of goat anti-human HRP conjugated secondary antibodies (product #2010-05, 
Southern Biotech) were added to each well.  Following 1 hr incubation at room 
temperature, the wells were rinsed 5 times with PBS.  Next, 100 μL of TMB One 
Solution (product #G7431, Promega), was added to each well and the enzymatic reaction 
was allowed to proceed for 10 minutes, after which it was quenched with 100 μL of 2 M 
H2SO4.  Finally, absorbance at 450 nm was measured using a Bio-Tek Synergy HT 
microplate reader.  The limit of detection was then determined using the assay’s linear 
range to calculate 3 standard deviations above background. 
RNA Isolation and Real-Time Reverse Transcription PCR (Real-Time RT-PCR).  
An RNeasy Mini Kit (product #74104, Qiagen) was used for RNA isolation.  300 µL of 
cell lysate was mixed with 400 µL lysis buffer (RLT) and homogenized by passing the 
sample through a 20 gauge needle 8 times.  700 µL of 70% was then added to the sample, 
and it was bound to an RNeasy spin column.  On the column, DNA was digested using an 
RNase-Free DNase Set (product #79254, Qiagen).  The remaining RNA was then washed 
with the appropriate buffers (RW1 and RPE).  After washing, the RNA was eluted in 50 
µL of nuclease-free water, and analyzed via real-time RT-PCR. 
Real-time RT-PCR was performed using a Rotor-Gene Q 5-Plex thermal cycler 
system (Qiagen, Alameda, CA).  Reactions were done in a 25 µL volume with 12.5 µL of 
2X One-Step qRT-PCR Buffer plus SYBR (product #639518, Clontech), 0.5 µL of 50X 
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QTaq DNA Polymerase Mix (product #639518, Clontech), 0.4 µL of 60X qRT Mix 
(product #639518, Clontech), 200 nM left and right primers (RSV primers, Table 2), 
nuclease-free water and 5 µL of sample.  Reverse transcription was performed at 48°C 
for 20 min followed by an initial QTaq DNA polymerase activation step of 95°C for 3 
min and 40 cycles of 95°C for 15 sec to denature, 60°C for 60 sec to anneal and extend, 
and 72°C for 15 sec to detect fluorescence.  Following amplification, a melt curve from 
50°C to 99°C was performed.  The limit of detection was then determined using the 
assay’s linear range to calculate 3 standard deviations above background.  
 
Results and Discussion 
 
To detect the antigen captured by MMPs, hybrid antibody-DNA probes were 
designed utilizing AuNPs to provide inherent amplification through antibody-tag DNA 
valency.  The AuNP acts as a scaffold to associate antibody recognition with a multiple 
DNA tags of a specific sequence.  Nanoparticles, specifically gold nanoparticles, were 
chosen because they are biologically compatible, provide a large surface area on which to 
couple multiple probes and allow the use of gold-thiol chemistry.38-41  Recently, AuNPs 
have been co-functionalized with antibodies and DNA for a number of applications.37, 42, 
43  The 15 nm AuNPs used in this study were functionalized with Synagis® antibodies 
(humanized monoclonal antibodies targeted to the RSV fusion protein) to bind to antigen 
captured by the MMPs.  The AuNPs were also functionalized with thiolated strands of 
DNA (Comp_55, Table 2) to provide a covalently attached DNA bonding site to which 
reporter DNA (Tag_76, Table 2)  can be hybridized.  The resulting AuNP contains both a 
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recognition component (Synagis®) and a signal generating component (Tag_76) which is 
released upon heating.  In the presence of antigen, the MMPs and AuNPs form a 
“sandwich” which can easily be separated from unbound AuNPs and cell debris using a 
magnetic field (Figure 22).  After washing, the Tag DNA of bound AuNPs is released 
and analyzed via PCR to detect the presence of antigen. 
 
 
Figure 22.  Illustration of the imunno-nanoparticle-PCR sandwich.  RSV antigen (green) is captured 
and separated using antibody functionalized 1 μm magnetic microparticles (gray).  The magnetic bead- 
antigen complex is then reacted with antibody-DNA functionalized 15 nm AuNPs (red).  Upon heating, 
hybridized DNA (blue) is released from the AuNPs and is analyzed via real-time PCR. 
 
The protein targeted in the designed assay, the F-protein of RSV, is a surface 
protein often targeted in direct antigen detection diagnostics because it is highly 
conserved between different strains of RSV.  Published studies have shown that the F-
protein of RSV has over 80% homology between different serotypes.44  Initially, virus in 
the analyte solution is captured using anti-F protein antibodies functionalized to MMPs.  
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MMPs were chosen as the capture antibody scaffold for three reasons.  First, attaching 
the antibodies to a microparticle as opposed to a microtiter plate allow for more thorough 
sampling of the analyte solution.  Secondly, MMPs allow for more thorough washing of 
captured antigen and AuNPs to decrease non-specific binding and reduce the background 
signal, which tends be a major drawback of I-PCR.45  Finally, the use of MMPs allows 
for ease of downstream automation in future applications.   
Magnetic Microparticle Pulldown of RSV Cell Lysate.  After attachment to 
MMPs, anti-RSV antibodies remain functional and effectively capture F-protein on RSV-
infected cell lysates.  To verify the functional attachment of anti-RSV antibodies to the 
MMPs, a pulldown experiment was performed.  After conjugation of F-mix antibodies to 
the MMPs, the functionalized MMPs were added to RSV-infected cell lysate.  An 
external magnetic field was used to extract captured virus.  Captured RSV was labeled by 
the addition of F-mix antibodies coupled to fluorescent 655 nm quantum dots.  Unbound 
quantum dots were removed by applying a magnetic field and washing.  After washing, 
the MMPs were imaged with a fluorescent microscope (Figure 23).  As a control, non-
functionalized MMPs were exposed to RSV, followed by pulldown and addition of 
antibodies coupled to quantum dots.  Figure 23A shows the fluorescence image from this 
experiment which contains negligible fluorescence.  In Figure 23B, the fluorescence was 
generated by the presence of the fluorescent quantum dot bound to the MMP-RSV 
complexes.  Formation of these complexes confirms that the antibodies remain functional 
after attachment to MMPs.  Examining the average pixel intensity over the entire 
fluorescence images revealed that the functionalized MMPs (33.9 average pixel intensity) 
generated 10-fold greater fluorescence over the control MMPs (3.2 average pixel  
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Figure 23.  Images of MMP-virus-QD complexes after magnetic pulldown experiments in RSV.  A 
mixture of MMPs unconjugated (left panels) or conjugated (right panels) to F-mix antibodies and 655 nm 
quantum dots conjugated to F-mix antibodies were mixed with RSV.  Magnetic particles and associated 
complexes were extracted and washed.  A) and C) Fluorescence and DIC images of unconjugated MMPs; 
B) and D) Fluorescence and DIC images of MMPs conjugated to F-mix antibodies.  The striated patterns in 
the DIC images are thought to be due to the accumulation of MMPs along magnetic field lines.  All images 
are 20x magnification. 
 
intensity).  DIC images (Figure 23C and 23D) both revealed striations due to the MMPs 
lining up when a magnetic field was applied in the bottom right corner of both images. 
Tag DNA-Gold Nanoparticle Functionalization.  Cofunctionalization of tag DNA 
and anti-RSV antibodies on 15 nm AuNPs offer a valency of up to 70 to 1.  To determine 
the number of Tag DNA molecules bound per AuNP, Tag DNA was incubated with 
samples containing antibody-CompDNA-AuNPs or a PB control.  Following incubation, 
both the sample and control were centrifuged to pellet AuNPs and any Tag DNA 
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hybridized to them.  The absorbance at 260 nm was then used to determine the amount of 
unbound Tag DNA in each supernatant.  These studies revealed that saturation of the 
AuNPs with Tag DNA, ~70 strands per particle, occurred when Tag DNA was incubated 
at a molar ratio ≥ 400:1 of Tag DNA:AuNP (Figure 24).  However, a much lower  
 
 
Figure 24.  Number of strands of Tag DNA bound per particle versus number of strands of Tag DNA 
added per particle.  Data shown as the mean ± S.D. (n = 3). 
 
concentration, 200:1, still allowed for the hybridization of ~50 strands per particle, which 
is the concentration that was used in subsequent experiments.  To verify the release of 
Tag DNA upon heating, antibody-CompDNA-AuNPs prior to Tag DNA hybridization 
and post Tag DNA hybridization were compared.  The supernatant of pre-hybridized 
conjugates after heating revealed that a small amount of Comp DNA had been released 
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from the AuNP, approximately 9 ± 1.3 strands per AuNP.  The post-hybridized 
supernatant had a much higher concentration of DNA.  After subtracting out the 
absorbance from the Comp DNA that was released, it was determined that approximately 
38 ± 0.9 strands of Tag DNA per AuNP was released upon heating.  Additionally, the 
260/280 absorbance ratio of the samples remained unchanged, assuring that the 
difference between samples was not due to the release of coupled antibodies. 
QCM Validation of Antibody-Gold Nanoparticle Attachment.  Upon 
functionalizing AuNPs with F-mix antibodies, their affinity for RSV greatly increases as 
compared to AuNPs conjugated to DNA alone (Figure 25).  RSV was bound via 
hydrophobic interactions to the gold electrode of a quartz crystal microbalance (QCM).  
This was followed by washing and blocking steps.  AuNPs functionalized with antibodies 
 
 
Figure 25.  QCM validation of AuNP binding.  Mass change of RSV exposed to AuNPs functionalized 
with either DNA alone (gray) or DNA and Synagis antibodies (black).  A) Entire experiment showing total 
mass bound upon flowing RSV onto the quartz crystal, followed by a PBS wash, blocking with 1% BSA, a 
second PBS wash, and finally functionalized AuNPs.  B)  The change in mass upon flowing functionalized 
AuNPs over the blocked and washed RSV infected cells. 
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and DNA were then flowed over the crystal and into contact with any bound RSV.  The 
binding of AuNPs to RSV resulted in a change of the crystal’s resonance frequency.  The 
degree of this change in frequency was used to determine the amount of mass bound to 
the crystal.  When antibody-DNA-AuNPs flowed along the crystal, binding occurred and 
can be observed by the 0.19 µg increase in mass detected by the microbalance (Figure 
25B).  However when DNA-AuNPs which were not functionalized with antibodies were 
flowed along the crystal, no significant change in mass was observed (Figure 25B).  
Although the channel on which DNA-AuNPs were flowed had less binding of infected 
cells, this did not affect the outcome of the results.  If the results are normalized to the 
mass of infected cells bound, the addition of antibody-DNA-AuNPs give an increase of 
9.93% while DNA-AuNPs actually give a decrease of 0.26%.  By comparing the addition 
of AuNPs with conjugated antibodies and DNA to the addition of AuNPs with DNA 
only, it is apparent that not only do antibodies coupled to the AuNP facilitate binding to 
RSV but also that AuNPs with DNA alone have very little non-specific binding to RSV, 
as evident by no change in mass under control conditions.   
Nanoparticle amplified immuno-PCR Detection of RSV.  Nanoparticle amplified 
immuno-PCR delivered >10,000 times more tag DNA to PCR analysis in RSV infected 
samples than uninfected control samples.  Evaluation of the NPA-IPCR assay was 
performed on RSV infected HEp-2 cell lysates and compared to uninfected HEp-2 cell 
lysates and PBS (Figure 26).  It is clear that there is a distinct shift in cycle threshold (Ct) 
between infected cells and both control samples.  The RSV samples, 8.3 x 106 PFU/mL, 
had an average Ct value of 8.49 while uninfected cells and PBS were much later, 21.9 and 
22.1 respectively.  Additionally, it is important to note that both the uninfected cells and  
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Figure 26.  RSV detection via nanoparticle amplified immuno-PCR.  A) Real-time PCR results of 
NPA-IPCR performed on RSV-infected HEp-2 cell lysates, uninfected HEp-2 cell lysates and PBS.  B)  
Comparison of the cycle thresholds of the same experiment.  Data shown as the mean ± S.D. (n = 3). 
 
PBS have amplification; however, they cross the cycle threshold later because there is a 
lower initial concentration of Tag DNA present in the uninfected and PBS samples.  This 
inherent background in I-PCR assays limits the sensitivity of this approach.46   
 To determine the lower limit of detection for NPA-IPCR, infected cells lysates 
were serially diluted and then assayed.  The same cell lysate stock was serial diluted and 
assayed via RT-PCR and ELISA.  ELISA was performed using the same antibodies as 
NPA-IPCR, to offer a direct comparison highlighting the inherent amplification potential 
of NPA-IPCR.  RT-PCR was performed using primers that target the N-gene because it is 
preferentially transcribed due to its location near the promoter; resulting in higher copy 
numbers than other transcripts.26   In order to compare all three methods, the signal 
generated from each was normalized (Figure 27).  The normalized signal is obtained by 
subtracting out noise of the assay and dividing each value by the response obtained at the 
highest virus concentration.  Both NPA-IPCR and RT-PCR have a substantially lower  
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Figure 27.  Detection of decreasing concentrations of RSV.  Comparison of RSV detection using 
ELISA, real-time RT-PCR and the developed NPA-IPCR assay.  Data shown as the mean ± S.D. (n = 3).   
 
limit of detection than ELISA.  The lower limit of detection for ELISA was 16,000 
PFU/mL, while RT-PCR was 17.9 PFU/mL and NPA-IPCR was 4.1 PFU/mL.  The limits 
of detection obtained for ELISA and RT-PCR in this study closely agree with previous 
studies and literature precedent (17,500 PFU/mL for ELISA and 14.13 PFU/mL for RT-
PCR).26, 47   
Although the dilution curves for NPA-IPCR and RT-PCR appear similar, the 
lower dilutions, shown in Figure 28, provide insight in determining why NPA-IPCR has 
a lower limit of detection than RT-PCR.  At lower virus concentrations, ≤ 8.3 PFU/mL, 
RT-PCR has more variation between replicates.  While both assays give an observable 
shift at 8.3 PFU/mL, only the NPA-IPCR is statistically above the limit of detection.  The  
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Figure 28.  Detection of low concentrations of RSV.  The number of standard deviations above 
background using both RT-PCR and NPA-IPCR at low virus concentrations.  The gray dashed line shows a 
3σ limit of detection.  Data shown as the mean ± S.D. (n = 3).  NPA-IPCR data has been shifted prevent 
overlapping with RT-PCR data.  
 
 
variability between replicates is due in part to the amount of amplification that is required 
to reach the cycle threshold, but may also be due to other properties of PCR.48  At a 
concentration of 8.3 PFU/mL, RT-PCR requires 29.1 cycles to reach the threshold while 
NPA-IPCR requires only 19.4 cycles.  NPA-IPCR effectively moved the low 
concentration dilutions up 10 cycles, in turn reducing the amount of PCR-induced 
variation between replicates.   
Both NPA-IPCR and RT-PCR have substantually different linear ranges than 
ELISA (Figure 29).  Although the linear range of ELISA goes up to 3.1 x 105 PFU/mL, 
no response is generated at virus concentrations below 1.2 x 104 PFU/mL.  On the other  
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Figure 29. Linear ranges of the compared assays.  Graphs showing the linear ranges of A) NPA-IPCR, 
B) RT-PCR, and C) ELISA. 
 
 
hand, the linear ranges of NPA-IPCR and RT-PCR cover multiple orders of magnitude.  
NPA-IPCR is linear up to approximately 1.0 x 104 PFU/mL after wich saturation begins 
to occur.  It is possible that adding higher concentrations of AuNPs could increase the 
viral titer at which saturation begins to occur.  However, even under the current 
conditions, the linear range covers 4 orders of magnitiude.  RT-PCR has a similar linear 
range to NPA-IPCR.  While RT-PCR does not show saturation at high virus 
concentrations, the difference between Cts at concentrations >1.0 x 104 PFU/mL no 
longer show a linear relationship with the Log2 transformed virus concentration. 
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Conclusions 
 
 The nanoparticle amplified immuno-PCR assay offers highly sensitive 
detection of respiratory syncytial virus in HEp-2 cell lysates.  The assay has a limit of 
detection better than RT-PCR detection of the RSV N-gene.  The NPA-IPCR assay 
has a number of areas that could further lower the limit of detection.  Larger AuNPs, 
such as 30 nm AuNPs, can be utilized to increase the surface area available for 
attaching Tag DNA.  More strands of Tag DNA per AuNP would increase the number 
of tags released per binding event, increasing the pre-PCR amplification of the NPA-
IPCR assay.  Additionally, a large background signal is a significant obstacle of I-
PCR assays, one that is present even in the nanoparticle-based assay.45, 46  Steps such 
as stringency washes could be taken to reduce this background and further decrease 
the limit of detection.  Although the NPA-IPCR still has room for improvement, it 
holds promise as a highly sensitive diagnostic.  
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CHAPTER IV 
 
THE POTENTIAL OF DNA LOGIC FOR IMPROVED IMMUNO-PCR BASED 
DIAGNOSTICS 
 
 
In order to begin treatment of a viral infection, the virus must first be accurately 
and quickly diagnosed.  Diagnostic methods should therefore be both sensitive and 
specific.  Inadequate sensitivity results in false negatives,1 while insufficient specificity 
results in false positives.2, 3  Although ultra-sensitive diagnostics exist, such as I-PCR, 
these assays are typically limited by the high-background associated with them.4-6  
However, it is possible to use the inherent information storing nature of DNA to increase 
not only the sensitivity, but also the specificity of an assay. 
 The concept of DNA logic was first introduced by Leonard Adleman in 1994 
when he demonstrated how intrinsic properties of DNA, such as base specific pairing, 
and the tools of molecular biology, such as PCR, could be used to solve the Hamiltonian 
Path Problem.7  The Hamiltonian Path Problem is to determine if a path exists in a 
directed graph, starting at the beginning vertex, ending at the ending vertex, and reaching 
each vertex exactly once.8  The problem is classified as NP-complete in complexity; and 
although with relatively few vertices, the problem appears quite simple, even a small 
increase in the number of vertices increases the complexity of the problem substantially.9-
11   
Adleman solved the problem by encoding each vertex with a unique 20-base 
DNA sequence (Figure 30).7  Edges between vertices were represented by 20-base DNA  
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Figure 30.  Truncated depiction of Adleman’s use of DNA to represent a directed graph.  Vertices and 
edges were represented by 20 base sequences.  Edges connecting to and from the starting and ending 
vertices were the exception, and instead were represented by 30 base sequences.  Edges were designed to 
hybridize to the two vertices that were connected by that particular edge.  Extended networks of vertices 
and edges would form to represent possible paths. 
 
sequences as well; these sequences were complementary to the last 10 bases of the vertex 
that was being departed and the first 10 bases of the vertex at which the edge arrived 
(unless the vertices involved were the starting or ending vertex, in which case the entire 
20 base sequence was used).  By mixing DNA representative of all of the vertices and 
edges, the edges hybridized to the vertices in such a way that all possible paths were 
formed.  Adleman then used DNA ligase to mend the discontinuities formed along the 
path sequences.  Primers specific to the vertices that represented the starting and ending 
vertices were used in PCR to amplify only routes that began and ended with the correct 
vertices.  Gel electrophoresis was used to select only the paths that were the correct 
length, long enough to touch each vertex only once.  Finally, affinity purification was 
used to select only paths that contained each vertex.  In the end, Adleman’s procedure 
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had reduced all possible paths to only those that started and ended at the correct vertex 
and touched each vertex only once.  It had isolated the Hamiltonian Path. 
 Since Adleman’s demonstration, the intrinsic properties of DNA have been used 
to build nanostructures,12, 13 molecular computational devices,14-16 biosensors17-19 and 
DNA scaffolds.20  Of noted interest is the development of the proximity ligation assay 
(Figure 31).21-23  The proximity ligation assay effectively added a logical AND (Λ)  
 
 
Figure 31.  Proximity ligation assay.  In the presence of antigen the proximity probes become spatial 
close, enabling the ligation and formation of the PCR template. 
 
operation to PCR-based antigen detection.24  The AND operation required the presence of 
two different antibodies or aptamers (proximity probes) binding to two different epitopes 
on an antigen to invoke a positive signal.23, 25  Each proximity probe was coupled to a 
unique single stranded DNA tag to act as the reporter, via PCR.21  The locations of the 
two epitopes were chosen such that when the two proximity probes would bind to their 
respective sites, they would be spatially close to each other.  This, in turn, would cause 
the DNA tags of each probe to be spatially close.  A ligation template would then be 
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added to the solution, and in the event that the probes were in close proximity to one 
another, the ligation template would ligate the two strands.  DNA ligase was then added 
to mend the nick in the two strands.26  This complete strand then acted as the template for 
PCR.  Primers specific to the complete template were added and only if the two strands 
had been ligated together would exponential amplification occur.  The assay increased 
specificity by requiring binding at epitope A AND binding at epitope B in order to 
generate a response. 
 Our research worked to extend this concept to create a Boolean logical NOT (¬) 
operation, which could effectively reduce the effects of nonspecific binding on ultra-
sensitive assays, such as I-PCR.  DNA logic tag sequences were hybridized to DNA 
covalently bound to gold nanoparticles (AuNPs, Figure 32).  Each DNA logic sequence 
is associated with a particular antibody through mutual attachment to the same AuNP.  In 
the presence of an antigen, the AuNPs functionalized with specific antibodies will bind to 
the desired epitope on the antigen.   A second construct, an antibody functionalized MMP 
is also added to the analyte solution in order to form a MMP-antigen-AuNP complex 
which can be separated from the rest of the analyte solution using an external magnetic 
field.  
The DNA logic tags are used as reporters, via PCR, of a binding event and 
designed to enable the performance of a Boolean logic NOT operation.  The NOT 
operation is designed to subtract the effects of non-specific binding prior to PCR 
amplification.  In doing so, the logic tags ensure that the resulting signal is a function of 
specific binding, NOT non-specific interactions.   
 
81 
 
 
Figure 32.  DNA logic NOT operation.  The NOT operation requires the use an antigen-specific probe 
(blue AuNP) and a non-specific probe (orange AuNP).  During antigen detection a number of AuNPs 
become non-specifically entrapped, represented by one orange and one blue AuNP not bound via an 
antibody interaction.  Upon heating, hybridized DNA is released and dsDNA is formed equivalent to the 
amount of non-specific binding.  A restriction enzyme is used to cut the dsDNA, and only the remaining 
DNA is available for PCR amplification. 
 
To perform the NOT operation, two types of AuNPs were added to the analyte 
solution. The first type of AuNP was functionalized with an antigen specific antibody and 
tag DNA (TagA, Table 3) that can be amplified using PCR.  The second type of AuNP 
was functionalized with an isotype matched non-specific antibody and tag DNA (TagA´, 
Table 3), which contained a restriction site that is complementary to TagA.  During 
separation, a certain number of AuNPs become entrapped in complexes without actually 
binding to an epitope, resulting in a non-specific signal.  With the second AuNP added,  
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Table 3.  Oligonucleotide sequences used in DNA logic studies. 
Name  Sequence 5´ → 3´ 
TagA 
CTGCGACGATCTACCATCGACGTACCAGGTCGGTTGAAGGACCGTGCATA
GCGAAATCTCAACTTACGAGACAAGC 
TagA´ 
TTCGCTATGCACGGTCCTTCAACCGACCTGGTACGTATCGACAGTTGACCGT
ACTTTACGTGGAGTACGCTTTACC 
Comp_TagA 
[C6Thiol]TTTTTTTTTTTTTTTGCTTGTCTCGTAAGTTGAGATTTCGCTATGCA
CGGTCCTT 
Comp_TagA´ 
[C6Thiol]TTTTTTTTTTTTTTTGGTAAAGCGTACTCCACGTAAAGTACGGTCA
ACTGTCGAT 
Comp_A* 
[C6Thiol]TTTTTTTTTTTTTTTGGTAAAGCGTACTCCACGTAAAGTACGGTCA
ACTGTCGAT 
Primer 1  GCTTGTCTCGTAAGTTGA 
Primer 2  CTGCGACGATCTACCAT 
 
 
the number of non-specifically trapped AuNPs should be roughly equal between both 
types of AuNPs.  Prior to PCR detection, the DNA was released from the AuNP and then 
annealed, forming double-stranded DNA (dsDNA) of TagA/TagA´.  Since TagA´ is 
essential for the formation of dsDNA, the amount of dsDNA formed was directly 
proportional to the number of non-specific AuNPs trapped during the pulldown.  A 
restriction enzyme that cleaves at the TagA/TagA´ restriction site was used to degrade the 
formed dsDNA.  Once degraded, the DNA no longer serves as a template for PCR.  In 
turn, the NOT operation removed the effects of non-specific binding on the final signal; 
and the remaining DNA, which is excess TagA (in the event an antigen is present) is 
amplified and detected using real-time PCR. 
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 Experimental  
 
Coupling of Antibodies to Magnetic Microparticles.  MagnaBind™ amine 
derivatized 1 μm magnetic microparticles were activated with sulfosuccinimidyl-4-[N-
maleimidomethyl]cyclohexane-1-carboxylate (Sulfo-SMCC).  In a typical reaction, 200 
μL of MMPs were washed three times with coupling buffer (CB) consisting of 50 mM 
phosphate buffer (pH 7.0), 0.15 M NaCl and 5 mM EDTA.  The MMPs were then cleared 
from the suspension using a magnet.  After 1 min, the solution became clear and MMPs 
were pulled to the side of the tube. When the clear supernatant and the external magnetic 
field were removed, the MMPs were resuspended in CB.  After washing, the MMPs were 
activated with 20 μL of 1 mM Sulfo-SMCC. The solution was mixed and allowed to sit at 
room temperature for 1 hr. The MMPs were then washed 3 times to remove excess Sulfo-
SMCC.  
Antibody reduction was coordinated so that once the MMPs were activated, they 
could be immediately used. Dithiothreitol (DTT) was used to reduce anti-RSV fusion 
protein antibodies (clones 1269 and 1214).  15 μL of 1.2 mM DTT was added to 15 μL of 
purified antibodies at 30 mg/mL in phosphate buffered saline (PBS). The solution was 
mixed and allowed to sit at room temperature for 0.5 hr. After that time, the antibodies 
were separated from DTT using a NAP-5 column.  The activated MMPs were combined 
with the column-purified reduced antibodies and allowed to react for 1 hr at room 
temperature. The conjugation was quenched by the addition of β-mercaptoethanol to a 
final concentration of 100 μM.  After 1 hr quenching, the MMPs were washed three times 
with PBS and then resuspended in a final volume of 300 μL. 
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Coupling of Antibodies and DNA to Gold Nanoparticles.  Thiolated DNA 
sequences were received as disulfides and were activated by cleaving the disulfide bond. 
Cleavage was performed in 100 mM DTT, 0.1 M phosphate buffer, pH 8.3. After 0.5 hr, 
thiolated DNA was desalted using Microcon YM-3 centrifugal filters. The purified DNA 
was resuspended in TE buffer and stored in small aliquots at -80°C.  
In a typical reaction, 35 μL of 0.2 mg/mL Synagis® antibody (humanized 
monoclonal antibody known to target the A antigenic site of RSV's fusion protein) or an 
isotype matched (human IgG1κ) antibody was added to 10 mL of 2.3 nM, 15 nm 
diameter AuNPs at pH 9.3 and placed on a rotator for 0.5 hr.  Then, 50.8 μL of 107 μM 
activated DNA (Comp_TagA or Comp_TagA´, Table 3) was added; the AuNPs were 
then rotated for another 0.5 hr. The solution was brought to 0.1 M NaCl, 10 mM 
phosphate buffer, and 0.02% Tween20 and allowed to sit for 1 hr. After this time, the 
concentration of NaCl was brought to 0.2 M and to 0.3 M after a third hour. Excess DNA 
was removed by centrifuging the solution for 20 minutes at 21,100 x gravity. The clear 
supernatant was then removed, and the red oily pellet was resuspended in a stock solution 
of 0.3 M NaCl, 10 mM phosphate buffer and 0.02% Tween20 (PB). This washing process 
was repeated three times. After washing, particles were resuspended, and Tag DNA 
(TagA or TagA´, Table 3) was added to bring the molar ratio of Tag DNA:AuNPs to 
200:1.  The solution was allowed to sit at room temperature overnight. Finally, excess 
Tag DNA was removed using the washing method described above.  
Preparation of RSV Infected Cell Lysate.  HEp-2 cells were cultured in OPTI-
MEM media supplemented with 2% fetal bovine serum, 250 µg/mL of amphotericin-B, 
10 mg/mL gentamicin and 200 mM L-glutamine and incubated at 37˚C with 5% CO2.  
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RSV stock was prepared by infecting a confluent T-150 flask of HEp-2 cells with RSV 
strain A2.  Infection was performed with rapidly thawed virus diluted to 5 mL in cell 
media.  Following the initial infections, cells were incubated for 1 hr after which 35 mL 
of cell media was added to the flask.  The infection was allowed to proceed for 4 days, 
after which cells were scraped from the surface of the T-150 flask. The supernatant 
containing the cells was collected in a 50 mL centrifuge tube and centrifuged for 5 min at 
500 x gravity.  Following removal of the supernatant, the cell pellet was resuspended to 5 
mL in cell media.  The cells were then frozen using a slurry of ethanol and dry ice in 
order to lyse cells and release virus particles. After freezing, the cells were thawed in a 
37°C water bath. The freezing/thawing cycle was repeated three times to ensure the 
release of virus particles from the cell wall. After the third cycle, the cells were 
centrifuged at 100 x gravity for 5 min to pellet large cellular debris.  The supernatant was 
then separated into aliquots of 0.5 mL and stored at -80°C.  
Restriction Enzyme Digest.  To test the NOT operation, TagA was hybridized 
with TagA´ and cleaved by the HpyCH4V restriction enzyme.  The reaction was prepared 
by adding various units of HpyCH4V (or NEB’s Diluent B for no enzyme controls) to 1 
µM TagA and 2 µM TagA´ in incubation buffer (50 mM potassium acetate, 20 mM Tris-
acetate, 10mM magenesium acetate, 1mM dithiothreitol, at pH 7.9) from New England 
Biolabs.  This mixture was then incubated at 37°C for 1 hour, followed by a heat 
inactivation step of 72°C for 25 minutes.  In order to verify the results, the samples were 
then examined using agarose gel electrophoresis and/or PCR.  
Agarose Gel Electrophoresis.  In order to verify the results from PCR and 
restriction enzyme digestion, agarose gels were run.  10 µL of samples from either 
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reaction was mixed with 2 µL 10X SYBR Gold in dimethylsulfoxide (DMSO), and 0.5 
µL 10X loading buffer.  The mixtures along with 4 µL EZ load 20 base pair DNA ladder 
combined with 2 µL SYBR Gold were run on a 4% agarose with Tris-Borate-EDTA gel 
for 30 minutes to 1 hour at 120 V.  The gels were then visualized under 254 nm 
ultraviolet light using the BioDoc-It Gel Documentation System. 
Real-Time Polymerase Chain Reaction (PCR).  Real-time PCR was performed 
using a SmartCycler II thermal cycler system.  Reactions were performed in a 25 µL 
volume with 12.5 µL of iTaq SYBR Green Supermix with ROX (0.4 mM dATP, 0.4 mM 
dCTP, 0.4 mM dGTP, 0.8 mM dUTP, iTaq DNA polymerase, 50 units/ml, 6 mM Mg+2, 
SYBR Green I dye, 1 µM ROX reference dye, and stabilizers), 200 nM left and right 
primers, and nuclease-free water.  The optimized protocol was a three-step PCR, 
beginning with an initial iTaq DNA polymerase activation step of 95°C for 3 minutes 
followed by 40 cycles of 95°C for 30 s to denature, 56°C for 30 s to anneal and extend, 
and 78°C for 6 s to detect fluorescence. 
 
Results and Discussion 
 
 RSV was used as a model to test the potential of the DNA Logic NOT operation 
on non-specific binding.  MMPs were functionalized with anti-RSV antibodies and used 
to capture RSV virions and infected cells.  After capture, two types of functionalized 
AuNPs were added to the solution.  The first type of AuNP was functionalized with RSV 
specific antibodies, covalently attached DNA (complementary to TagA), and TagA DNA 
hybridized to the covalently bound strand.  The second type of AuNP was functionalized 
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with isotype matched non-specific antibodies, covalently attached DNA (complementary 
to TagA´), and TagA´ DNA hybridized to the covalently bound strand.  After magnetic 
separation of the MMP-RSV-AuNP complex, the solution was heated to 95ºC to release 
both TagA and TagA´ entrapped in the complex.  The released DNA was allowed to 
hybridize to form TagA/TagA´ dsDNA, and then digested with a restriction enzyme 
(HpyCH4V).  The digested DNA was then analyzed via real-time PCR (Figure 33). 
Upon performing the NOT operation, it was clear that the shift in cycle threshold 
(Ct) indicative of DNA cleavage occurring was not present (Figure 33).  The Ct values of 
samples before and after the restriction enzyme digest were too similar to conclude that 
the dsDNA had been cut.  However, pertinent information still existed in the experiment.   
 
Figure 33.  PCR analysis of an initial attempt at the NOT operation.  Samples incubated with RSV 
(blue & red) had a distinctive shift when compared to samples incubated in PBS (green & gold).  The PBS 
samples represent the high background associated with I-PCR, which the NOT operation seeks to reduce.  
Samples incubated with the restriction enzyme HpyCH4V (red & gold), had no distinguishable shift when 
compared to no enzyme control samples (blue & green). 
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First, it was clear that in the presence of infected cell lysates, the Ct shifted approximately 
10 cycles earlier indicating that substantially more TagA DNA was present than when the 
reaction was performed in PBS.  Second, non-specific binding occurred, which was 
observed by the fact that the PBS control samples have an earlier Ct than no template 
controls (negative control).  It is this inherent background that the NOT operation seeks 
to reduce.  The background signal, present because TagA DNA is added to all samples, 
even RSV negative samples, limits the sensitivity of I-PCR.27, 28 
To determine whether the problem with the NOT operation was in the antigen-
complexing steps or in the actual restriction enzyme digestion and subsequent PCR, stock 
solutions of TagA and TagA´ were used to validate digestion and PCR detection.  
Femtomolar concentrations of TagA and TagA´ were directly combined at room 
temperature and allowed to hybridize.  The sample was diluted in incubation buffer and 
then split in half.  Restriction enzyme was added to one sample, and the other served as a 
no enzyme control and Diluent B was added.  Both samples were incubated at 37°C and 
then heat-inactivated prior to PCR analysis.  PCR analysis showed no shift in samples 
treated with restriction enzyme when compared to a no enzyme control (Figure 34).   
High concentrations (uM) were used to optimize and visualize the restriction 
digest via gel electrophoresis.  The first factor evaluated was hybridization temperature.  
Hybridization temperature was significant because dsDNA formation is essential in DNA 
cleavage occurring.  In order for the logic operation to occur, TagA and TagA´ must 
anneal to become dsDNA.  Only then will the restriction enzyme cut the DNA and 
subtract out the non-specific binding.  Gel electrophoresis was used to verify dsDNA 
formation (Figure 35).  As Figure 35 shows, annealing is sensitive to temperature and 
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Figure 34.  NOT operation controls.  Femtomolar concentrations of TagA and TagA´ directly combined 
showed no shift in Ct upon incubation with the restriction enzyme HpyCH4V.  Additionally, TagA´ alone 
did not amplify during PCR (red). 
 
 
Figure 35.  dsDNA formation of TagA/TagA´.  Lane 1: 10-bp ladder.  Lane 2: Single stranded TagA 
DNA.  Lane 3: Single stranded TagA´ DNA (TagA complement).  Lane 4: Equal molar ratios of TagA and 
TagA´ at room temp.  Lanes 5 through 12: Equal molar ratios of TagA and TagA´ annealed for 20 minutes 
at increasing temperatures (60 – 95 °C). 
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increased temperature is needed to completely anneal equimolar ratios of TagA and 
TagA´.  When TagA and TagA´ were combined at room temperature, no shift in 
electrophoretic mobility is observed.  Not until 20 min at 80°C does the TagA/TagA´ 
band begin to shift, indicating formation of dsDNA.  It took 20 min at 90°C, for the band 
to completely shift.  With this information it was determined that an annealing of 20 
minutes at 90ºC (lane 11) was required prior to enzymatic digestion.  
 Using the optimized annealing temperature, the restriction digest was repeated at 
a high concentration to allow visualization via gel electrophoresis instead of PCR.  
Figure 36 shows, at high concentrations, cleavage of the dsDNA occurs.  Lane 4 verifies 
that prior to the restriction digest, TagA/TagA´ is double stranded.  Although time does  
 
 
Figure 36.  Time dependant cleavage of dsDNA.  Lane 1: 10-bp ladder.  Lane 2: Single stranded TagA 
DNA.  Lane 3: Single stranded TagA´ DNA (TagA complement).  Lane 4: dsDNA after cleavage 
conditions for 60 min without restriction enzyme present.  Lanes 5 through 11: dsDNA after increasing 
cleavage times (1, 5, 15, 30, 60, 120, 240 mins) in the presence of HpyCH4V. 
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have some effect on the extent of cleavage, the vast majority of cleavage is accomplished 
in the 1st minute (lane 5).  These same samples were diluted to PCR acceptable 
concentrations and a shift in Ct can be seen (Figure 37A).  Figure 37B shows that after 1 
min of cleavage, a shift of approximately 3.5 cycles is observed which is equivalent to 
approximately 91% less template available for PCR.  After 240 min of cleavage, which 
by visualization on the gel can serve as an endpoint of the reaction, a shift of 
approximately 5 cycles is observed, equivalent to approximately 97% cleavage. 
 
 
Figure 37.  Shift in Ct generated by extended cleavage times.  A) Samples annealed and cleaved at 
micromolar concentrations show a shift upon dilution and PCR analysis.  B) The vast majority of cleavage 
occurs in the first min with a shift of 3.5 cycles.  However, extended times, 240 min, increased the shift to 5 
cycles. 
 
These results make it apparent that PCR is effective at detecting cleavage of 
dsDNA; however when the optimized restriction digest conditions were used to repeat the 
experiment shown in Figure 34, no shift was observed post-cleavage (data not shown).  
The only difference between the gel-based studies and the repeated experiment was the 
DNA concentration at which the restriction digest was performed.  To enable the gel-
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based studies to be visualized, the reaction was performed at µM concentrations and then 
diluted for PCR analysis.  However, for the PCR-based experiments the restriction digest 
was performed at fM concentrations. 
In order to test the DNA concentration dependence of the restriction digest, the 
digest was repeated at decreasing concentrations and analyzed via PCR.  Figure 38 
shows that as the concentration at which the restriction digest is performed decreases the 
ΔCt, which represents the amount of cleavage that has occurred, also decreases.  At 
concentrations above 10 nM, the PCR analysis becomes problematic because the  
 
 
Figure 38.  dsDNA concentration dependence of the restriction digest.  At micromolar and high 
nanomolar concentration of dsDNA, a shift between before and after enzyme digested samples is observed.  
However, at low nanomolar concentrations the restriction enzyme needs to be present at 100-fold excess to 
observe a shift.  When the concentration of dsDNA is picomolar, even a 100-fold excess of restriction 
enzyme does not generate as shift. 
 
concentration of template DNA is too high to obtain a 5 cycle baseline.  Although 
quantitation at these concentrations is difficult, it is easy to observe that a shift in Ct does 
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occur after the restriction digest.  At 1 µM and 100 nM dsDNA concentrations, restriction 
enzyme at both a 1x concentration and a 100x concentration effectively cut the dsDNA 
(Figure 39).  However, at lower concentrations (10 nM to 1 nM dsDNA) cleavage only  
 
Figure 39.  Delta Ct at decreasing dsDNA concentrations.  Micromolar and high nanomolar 
concentrations of dsDNA must be considered with the knowledge that they are too high for accurate 
quantitation via PCR.  However, examining 10 nanomolar and less concentrations reveals that the shift in 
Ct decreases as dsDNA concentration decreases. 
 
 
occurs in extreme excess of restriction enzyme (100x).  After the concentration of 
dsDNA is ≤10 pM, no cleavage is observed even in the presence of 100x restriction 
enzyme.  It was clear that as very low concentrations of TagA/TagA´ dsDNA, no feasible 
concentration of restriction enzyme would facilitate the NOT operation.  The pertinent 
question then was what would be the concentration of DNA in a cleavage reaction for an 
actual pull down experiment.  Figure 40 shows that a positive control sample results in a 
concentration of ~5 pM TagA.  A PBS control sample, which represents the  
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Figure 40.  TagA DNA concentrations generated via antigen pulldown.  The concentration of TagA 
pulled down in an RSV positive reaction (black) is ≤ 5 pM.  The background signal generated in a PBS 
reaction (red) is much less, in the femtomolar range. 
 
concentration that would actually be subtracted, is in the fM range.  Unfortunately, this is 
below the limit at which the restriction reaction seems to function properly.   
The possibility remains that the kinetics we have been working with are unique to 
the HpyCH4V enzyme we have been using, and that a different enzyme might be more 
amicable to the NOT operation.  Fortunately, TagA and TagA´ were designed to have a 
second Rsa1 restriction site.  The restriction digest was repeated at µM concentrations, 
using HpyCH4V, Rsa1, or a combination of both (Figure 41).  It is clear from lanes 6 
and 9 that in the presence of both enzymes, the TagA/TagA´ dsDNA gets cut into smaller 
fragments.  However, Figure 42A reveals that this doesn’t have an effect on the PCR 
results.  An equivalent shift in Ct is achieved from using only HpyCH4V as compared to  
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Figure 41.  Gel electrophoresis of dsDNA cleaved with multiple restriction enzymes.  Lane 1: 10-bp 
ladder.  Lane 2: Single stranded TagA DNA.  Lane 3: Single stranded TagA´ DNA (TagA complement).  
Lane 4: dsDNA after digest for 240 min in HpyCH4V-specific buffer (no enzyme present).  Lane 5: 
dsDNA after digest for 240 min with HpyCH4V in HpyCH4V-specific buffer.  Lane 6: dsDNA after digest 
for 240 min with HpyCH4V and Rsa1 in HpyCH4V-specific buffer.  Lane 7: dsDNA after digest for 240 
min in Rsa1-specific buffer (no enzyme present).  Lane 8: dsDNA after digest for 240 min with Rsa1 in 
Rsa1-specific buffer.  Lane 9: dsDNA after digest for 240 min with Rsa1 and HpyCH4V in Rsa1-specific 
buffer. 
 
 
 
Figure 1.  PCR analysis of multiple enzyme cleavage.  A) When performed at micromolar concentrations 
and then diluted for PCR analysis, a shift is observed after dsDNA cleavage.  B) However, the shift 
generated from using both HpyCH4V and Rsa1 (both) is no greater than the shift generated by only 
cleaving with HpyCH4V. 
96 
 
a combination of HpyCH4V and Rsa1 (Figure 42B).  The smallest shift in Ct resulted 
from using only Rsa1 to digest the dsDNA (data not shown). 
Therefore, non-enzymatic means of subtracting out non-specific binding were 
explored.  One of the promising methods explored was the use of functionalized AuNPs 
to specifically capture dsDNA.  Following capture, the AuNPs were then centrifuged to 
remove the non-specific binding prior to PCR amplification.  In these experiments, 
AuNPs were functionalized with DNA (A*) which was used to capture dsDNA (Figure 
43).  A* was designed to be complementary to the 3´ end of TagA´.  In the event of non-
specific binding, TagA´ would hybridize to TagA as shown earlier. After the formation of 
TagA/TagA´ dsDNA, AuNPs functionalized with A* are added to the sample and  
 
 
Figure 43.  Representation of using A* AuNPs to remove dsDNA.  Upon formation of dsDNA, the 3´ 
end of TagA´ is used to hybridize to A* which is functionalized to a 15 nm AuNP.  After hybridization 
with A*, centrifugation is used to remove the AuNPs, and in turn, dsDNA. 
 
97 
 
allowed to hybridize to the free 3´ end of TagA´.  The AuNPs were then centrifuged and 
pulled down any hybridized DNA with them.  The supernatant was then removed and 
analyzed via PCR. 
As Figure 44 shows, the use of A* functionalized AuNPs resulted in significant 
ΔCts, even at low fM concentration.  In these experiments the concentration of A* 
AuNPs used to pulldown dsDNA was 5 pM.  At this concentration of AuNPs, 1 fM of  
 
Figure 44.  Removal of dsDNA using A* AuNPs.  At femtomolar concentrations of dsDNA, the A* 
AuNPs effectively removed 97% of the dsDNA (black & gray).  However, at picomolar concentrations the 
AuNPs removed only 50% of the dsDNA (red & green).  In both cases, the presence of TagA´ was required 
to result in a shift in Ct. 
 
dsDNA was shifted 5 cycles, indicating a 97% decrease in TagA.  At higher 
concentrations of dsDNA (1 pM), the shift was less significant, but still present.  It is 
possible that excess concentrations of AuNPs are required to capture the dsDNA, 
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therefore more AuNPs may be needed to capture pM concentrations of dsDNA.  In either 
case, the pulldown is specific to TagA/TagA´ complexes because no shift is observed 
when A* AuNPs are incubated directly with TagA.  In an attempt to pulldown higher 
concentrations of dsDNA, 1 nM A* AuNPs was used in the pulldown (Figure 45).  It is 
apparent that the variation between replicates becomes quite large in the presence of 1 
nM concentrations of AuNPs.  It is possible that at these concentrations not all of the 
AuNPs are being removed prior to PCR, and they are then interfering with the PCR.  
Even the TagA/A* AuNP control sample becomes noisy, which indicates that the 
variation is not due to variable amounts of dsDNA being pulled down, but rather, a 
 
 
Figure 45.  Using nanomolar AuNPs to remove dsDNA.  The use of nanomolar concentrations of A* 
AuNPs results in increased noise during the PCR analysis. 
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variation in the PCR.  It is possible that centrifuging the AuNPs at higher speeds than 
16,100 x gravity (as used in this experiment) might reduce the variation. 
 
 
Conclusions 
 
 The use of DNA logic, specifically a Boolean NOT operation, offers the potential 
to reduce the effects of non-specific binding in certain protein detection assays.  DNA 
logic can be utilized in assays such as immuno-PCR where an antigen is detected via a 
protein interaction, and then the detection is reported via a DNA probe.  The logic 
operation uses the information stored in unique DNA sequences to perform a NOT 
operation on the DNA prior to the detection being reported.  The simplest approach to 
removing non-specific DNA is to force the DNA from non-specific binding into a double 
stranded formation, and then remove the dsDNA.  Although an enzymatic based NOT 
operation proved unsuccessful, the principle remains: removing non-specific reporter 
DNA prior to PCR.  Other methods such as physically removing the DNA via 
centrifugation can result in the desired effect without using enzymes.  The use of DNA 
functionalized AuNPs effectively removed 97% of dsDNA, which in an I-PCR assay 
would be representative of non-specific binding.  If the AuNP removal was optimized, it 
is possible that even more dsDNA could be removed prior to amplification.  However, 
even reducing the background signal 97% could substantially increase of the sensitivity 
of an I-PCR based assay. 
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